Compositions comprising avenanthramide or its analogues having improved stability

Abstract

To provide compositions comprising avenanthramides or analogs thereof having improved stability during storage while stabilization does not lead to discoloration.SOLUTION: Disclosed is a composition comprising an avenanthramide and a stabilizer, where (a1) the avenanthramide is avenanthramide C; and (a2) the stabilizer is selected from the group consisting of EDTA or a salt thereof, ascorbic acid, citric acid, lactic acid, 4-hydroxyacetophenone, malic acid, tartaric acid, tetrasodium glutamate diacetate, trisodium ethylenediamine disuccinate, phytic acid, 6-paradol and a mixture thereof.SELECTED DRAWING: None

Description

[Technical Field]

[0001] The present invention generally relates to at least one avenanthramide or its analogue, or modified Contains oat extract with improved stability, including avenanthramide or its analogues. or compositions thereof; their cosmetic or medical use; food, nutritional supplements Use of such compositions for preparing supplemental foods, cosmetics, pharmaceuticals or veterinary preparations; Furthermore, foods, nutritional supplements, cosmetics, pharmaceuticals or veterinary preparations containing such compositions Regarding this, finally, the present invention relates to the stabilization of avenantramide. Regarding specific stabilizers for this purpose. [Background technology]

[0002] Poaceae is also known as Gramineae and is a well-known family of grasses. Poaceae are a large and almost ubiquitous family of monocotyledonous flowering plants. It is an economically important family of goods. Grasses have been used as livestock feed for 6,000 years. They are cultivated and produce grains from grasses, such as wheat, rice, and corn. Barley, sorghum, millets, and oats remain among the most important foods for humans. It is an object.

[0003] Cereal grains contain many unique substances among biologically active compounds. For example, edible fibers (arabinoxylan, β-glucan, cellulose, lignin and li Gunans, sterols, tocopherols, tocotrienols, phenolic compounds, vitamins It is an excellent source of mine and trace elements.

[0004] Oatmeal is a soothing agent that relieves itching and irritation associated with various dry skin conditions. It has been used for centuries. Medical textbooks describe automy for various skin conditions. It facilitated the topical application of oatmeal flour. Common clinical applications include treating itchy skin conditions such as atopic dermatitis and allergies. It is a clinical application as an adjunctive therapy for sexual or irritant contact dermatitis. Direct oat The specific antistimulant activity has been established in both in vitro and clinical studies. The excrete is the ionophore-stimulated release of arachidonic acid from phospholipids in keratinocytes. It has been shown to reduce and inhibit prostaglandin biosynthesis. Despite its widespread use, the phytochemistry present in oats that mediates anti-inflammatory activity remains unclear. There are few studies that have investigated the substance.

[0005] Oats consist of two main species: Avena sativa L. and Avena nu da L. (Synonym: Avena sativa by Gillet and Magne) subsp.nuda(L.), and Avena sativa v by Koern It is found in ar.nuda (L.) and other species. A. sativa is found in oats or in the shell. It is also known as oat, and thrives in cold temperate climates, especially in the cold and humid climates of Northern Europe and North America. It is mainly cultivated in the area. A. nuda has its shell removed when the harvested product is collected. Therefore, it has a hull-free threshing property similar to wheat, so it can be hulled or hulled. It is known as the oat. Oats in the shell make up the majority of global oat production. This is representative, however, excluding China, where the naked oat is the most common species.

[0006] The composition of emmer mainly consists of starch (65 - 85%), protein (15 - 20%, including enzymes), lipids (3 - 11%) and about 2 - 8.5% dietary fiber containing a high content of β-glucan. Emmer also contains other important bioactive compounds, such as phenolic compounds.

[0007] A general definition of phenolic compounds is any compound containing a benzene ring with one or more hydroxyl groups. Examples are phenolic acids, flavonoids, condensed tannins, coumarins and alkylresorcinols. In grains, these compounds are mainly located within the pericarp and can be concentrated by hulling the grains to produce bran.

[0008]

[0009] -Scavenges radicals and donates hydrogen atoms or electrons, or chelate metal cations. This is related to the ability of phenolic compounds [Dykes et al., Cereal Foods] [World, 2007, pp. 105-111]. Phenolic compounds have antioxidant properties. It contains, and therefore, reactive oxygen species (i.e., superoxide anion, hydroxyl group and Protecting against degenerative diseases (e.g., heart disease and cancer) involving peroxy groups can.

[0008] The types and concentrations of phenolic compounds in whole wheat grains are related to the plant diversity and properties of the grain. They are more affected by high levels of phenolic acids, tocopherols, and alkyl(alkyl) acids. In addition to containing a nyl)resorcinol derivative, oats are particularly avenanthramide (Avns; N-cinnamoyl anthranilate alkaloid or anthranilate amine) It is a unique source (known as a cereal) that is not found in other grains. These compounds These are anti-pathogenic bacteria, produced by plants in response to exposure to pathogens such as fungi. .

[0009] Avenanthramide (hereinafter referred to as Avns or a single avenanthramide compound) Avn (abbreviated as Avn) is anthranilic acid and hydroxycinnamate that have an amide bond. It is a low molecular weight phenolic amide containing an acidic moiety, and A. sativa and A. nud a is also a group of naturally occurring phenolic amides in oats. These are found in fungi, etc. Phytoalexins, which are produced by plants in response to exposure to pathogens, and the first identified... Oats contain a unique group of approximately 40 different types of Avns, which are oats. It is present in both grains and leaves. The most abundant is Avn A(N-(4'-hydroxysine Namoyl)-5-hydroxyanthranilic acid), Avn B (N-(4'-hydroxy- 3'-Methoxycinnamoyl)-5-hydroxyanthranilic acid) and Avn C(N -(3'-4'-dihydroxycinnamoyl)-5-hydroxyanthranilic acid These are amides of 5-hydroxyanthranilic acid, p-coumarin, ferula and They contain caffeine and hydroxycinnamic acid, respectively. These Avns are constitutively derived from seeds. These are present and appear in almost all ground fractions, but their highest concentrations are in bran and seeds. [Boz H, Czech Journal of Food] Sciences, 2015, Vol. 33 (No. 5): pp. 399-404. Oat grain The total avenanthramide (Avns) content varies depending on the variety and agricultural treatment, but is approximately 2- It was found to be 700 mg / kg (0.0002-0.07%) [Maliaro va M et al., Journal of the Brazilian Chemical [Society, 2015, Vol. 26 (No. 11), pp. 2369-2378].

[0010] The extraction of Avns from oats can be performed using various solvent compositions, e.g., pure or diluted The experiment was conducted using ethanol and methanol. The results were obtained at different times at room temperature or under controlled conditions. Under heated conditions, the extraction procedure is performed using, for example, naked oats, 50% aqueous ethanol, etc. Achieved [Tong L et al., Journal of Integrative Aggregation] [iculture, 2014, Vol. 13, p. 1809]

[0011] Maliarova, M. et al., Journal of the Brazilian Chemical Society, 2015, Vol. 26 (No. 11), pp. 2369-2378 The page discusses the extraction of Avns from naked oat bran using methanol and ethanol. The efficiency of isopropanol was compared. The optimal conditions for the highest yield of Avns were The methanol concentration was 70%, the extraction temperature was 55°C, and the extraction time was 165 minutes.

[0012] Abenanthramide exhibits excellent antioxidant activity both in vitro and in vivo. Furthermore, oxidative dysfunction of cells and oxidative stress-related diseases, such as neurodegeneration and cardiovascular disease. Anti-inflammatory, anti-irritant, anti-atheromatous, and anti-proliferative properties that can prevent or limit the development of vascular diseases. It has proliferative activity and provides additional protection against skin irritation, aging, CHD, and cancer. Several studies have demonstrated the potential of avenanthramide in therapeutic applications. It is increasing [Perrelli A et al., Oxidative Medicine a nd Cellular Longevity, 2018, DOI:10.1155 / 2 [018 / 6015351]

[0013] The antioxidant activity of Avns is due to typical cereal components such as ferulic acid, gentisic acid, and p-hydride. Roxybenzoic acid, protocagtechuic acid, silicic acid It was found to have 10 to 30 times higher antioxidant activity than ingic acid, valine acid, and vanillin. Avns have different antioxidant activities, with Avn C having the highest activity, followed by Avn B and A vn A follows. Oat extract rich in Avns was LD in vitro. It inhibits L-oxidation. The antioxidant properties of oats lower serum cholesterol and LDL cholesterol. It has the potential to reduce cardiovascular risk by inhibiting tetraglyceride oxidation and peroxidation. This has been confirmed in both animal studies and human clinical trials. Consumption of these foods increases the risk of colon cancer not only due to their high fiber content, but also due to Avns. Another study showed that it can reduce sexual activity. Furthermore, oat extracts rich in Avns The substance has been shown to inhibit atherosclerosis and the activation of NF-κB transcription factors. Furthermore, NF-κB transcription factors are modulodents of infection and inflammation [Hueseyin B oz, Phenolic Amides (Avenanthramides) in Oa ts-A Review, Czech J. Food Sci., Vol. 33, 2015 (5 [Issue number), pages 399-404].

[0014] WO2004 / 047833A1 describes the substance P-induced release of histamine from mast cells. This document describes the treatment and prevention of itching caused by inhibition and the substance of formula 2 above.

[0015] WO2017 / 159964A1 is active for preventing or treating hearing loss. This document describes compositions containing avenanthramide or its derivatives as ingredients.

[0016] EP0157420A2 is a 5-lipoxygenase inhibitor containing avenanthramide L This document describes avenanthramides that include compounds structurally related to them.

[0017] Lotts T et al., Experimental Dermatology, 2017, Volume 26 (Issue 8): Pages 739-742 contain information on dihydroavenanthramide D (CAS 697) 235-49-7, INCI name: Hydroxyphenylpropamide benzoic acid; Symris The active ingredient in SymCalmin (registered trademark) provided by e) how obesity cells It inhibits vesicular degranulation and exerts anti-inflammatory effects through interaction with neurokinin-1 receptors. This document describes the following.

[0018] Cereal phenolic compounds, particularly avenanthramides, possess potent beneficial biological activity. As a result, avenanthramide can be administered orally to humans and animals and / or Valuable and highly promising for topical application, nutritional, cosmetic, and health uses. It contains a rich, natural active ingredient.

[0019] Therefore, it remains stable during processing steps, storage, or transport, does not decompose, and is also light-resistant. Furthermore, they are also stabilized by UV irradiation, metal cations, air, or certain enzymes. It is based on naturally occurring, well-tolerated, biodegradable materials that do not decompose, especially on the skin. Novel formulations for use in protection and for the prevention and / or treatment of skin diseases. There is a continuing need for development in the food, cosmetics, pharmaceutical and veterinary industries. Consumer demand exists.

[0020] Oxidative decomposition and auto-oxidation processes play a crucial role in the stability of the preparation. This is because these can destroy the desired components, and therefore these desired components If it is not present, it will produce unpleasant or unwanted decomposition products, or the products will have a discoloration or other undesirable properties. This can negatively impact the rational performance characteristics, and therefore, in many cases, the value of the product. This is because it reduces it.

[0021] Abenanthramide has found applications in the nutrition, cosmetics, pharmaceutical, or veterinary industries. However, due to their chemical structure, these are unstable compounds. Phenolic acids Antioxidant activity is related to the number and position of hydroxyl groups within the molecule. (Monophenol) The antioxidant efficiency is strongly enhanced by the introduction of a second hydroxyl group at the ortho or para position. This yields one or two methoxy substituents at the ortho position relative to the hydroxyl group. This increases the oxidation of other compounds. Therefore, avenanthramide compounds reduce the oxidation of other compounds. To cause or inhibit the oxidation of other compounds. Nslamide compounds themselves are oxidized, that is, they decompose over time. This means that avenanthramide, as an active substance or active ingredient, is no longer present. Alternatively, it may only be present at trace concentrations, which is unfavorable to the composition or final product. ru.

[0022] Among avenanthramide compounds, avenanthramide C is particularly known for its low stability. This leads to rapid instability during storage.

[0023] Therefore, in order to maintain the activity of avenanthramide as an active substance or active ingredient to extend the shelf life of compositions or preparations containing avenanthramide compounds. The composition or preparation shall be stabilized.

[0024] Stabilizing a composition containing one type of avenanthramide or a mixture of avenanthramides. Therefore, vitamin C (ascorbic acid) has been used to this day. However, higher concentrations The use of certain amounts of vitamin C (ascorbic acid) can cause unpleasant discoloration of the composition, thus affecting the product. It reduces value. In particular, in final formulations such as emulsions, vitamin C (ascorbic acid) Stabilization results in undesirable discoloration. Other avenanthramides (avenat The use of hramide stabilizers is not yet known.

[0025] Therefore, achieving therapeutic concentrations or bioavailability of avenanthramide substances It is extremely difficult to accomplish. [Overview of the project] [Problems that the invention aims to solve]

[0026] Therefore, the object of the present invention is to exhibit enhanced stability during storage, while maintaining stability and preventing discoloration. Compositions containing avenanthramide or its analogues that do not result in avenanthramide The objective is to provide an oat extract containing mid or its analogues.

[0027] In particular, the objective of the present invention is to stabilize avenanthramide in a composition or oat extract. This can be done, and therefore the beneficial biological activity and formulation properties of avenanthramide itself Natural, biodegradable, cosmetically or pharmaceutically acceptable, safe, that does not interfere with The objective of this invention is to propose a stabilizer substance that is easy to use and stable. avenanthramide compounds in the composition or oat extract, particularly avenanthramide A, B, C or L or avenanthramide analog compound dihydroavenanthramide D ( 2-{[3-(4-hydroxyphenyl)propanoyl]amino}benzoic acid; INCI name Stabilizing hydroxyphenylpropamide benzoic acid (CAS 697235-49-7). It can be used as a cosmetic or pharmaceutical product, and is natural, biodegradable, and does not cause discoloration. To propose a stabilizer substance that is acceptable in minutes, safe, easy to use, and stable. That is the case.

[0028] Surprisingly, avenanthramide, especially avenanthramide Abenanthramide C, the most unstable of the three, is particularly unstable as a stabilizer, especially at low concentrations, and especially as a chlorine stabilizer. A stabilizer which is a nitrifying agent, an organic acid, an antioxidant, or a mixture thereof, or at least one of these. It was subsequently found that this could significantly stabilize the product. (Part of the aforementioned combination of stabilizers) Synergistic effects can even be demonstrated for this. This is especially true for at least one type of avena. The nslamide analog is dihydroavennanceramide D(2-{[3-(4-hydroxyphenyl This applies when the acid is propanoyl aminobenzoic acid. [Means for solving the problem]

[0029] The above-mentioned objective is achieved according to a first aspect of the present invention, (i) at least one avenanthramide or analog thereof, or at least one Oats containing evananthramide or its analogues Extracts, and (ii) Selected from the group consisting of chelating agents, organic acids, antioxidants, and mixtures thereof. at least one type of stabilizer This is achieved by providing a composition containing or consisting of these. In a second aspect, the present invention relates to the use of the composition as a cosmetic, particularly for skin protection and In skin care, scalp protection and scalp care, hair care, nail care, or skin condition, Unbearable and sensitive skin, skin irritation, skin redness, wheals, pruritus (itching), skin aging, Wrinkle formation, decrease in skin volume, loss of skin elasticity, pigment spots, pigment abnormalities, or dry skin, Dermatological cosmetics in the prevention and / or treatment of dry skin requiring skin moisturizing Regarding use.

[0030] In a third aspect, the present invention relates particularly to skin diseases or keratinized diseases, and in particular to inflammation related to the barrier. It contains symptomatic, immunoallergic, atherogenic, xerogenic, or hyperproliferative components. In the prevention and / or treatment of skin diseases or keratinized diseases, or in the generation of ROS In the prevention and / or treatment of skin diseases associated with the increase in, or cardiovascular diseases, In the prevention and / or treatment of allergic reactions and coronary heart disease, serum LDL cholesterol Insulin to lower blood pressure, to reduce sterol and lipid levels For use in pharmaceuticals to improve blood glucose sensitivity and to enable blood glucose control. This relates to the use of the aforementioned composition as such.

[0031] In a fourth aspect, the present invention relates to foods, nutritional supplements, cosmetics, pharmaceuticals and veterinary preparations. This relates to the use of the aforementioned composition for preparation.

[0032] In a fifth aspect, the present invention relates to a food, nutritional supplement, or cosmetic comprising a composition according to the present invention. , relating to pharmaceuticals and veterinary preparations.

[0033] Finally, the present invention relates to the stabilization of avenanthramide or avenanthramide analog compounds. The use of one or more of the aforementioned stabilizers for the purpose of

[0034] The present invention is defined in the appended claims. However, the present invention itself is also defined in the appended claims. Its preferred variations, other purposes, and advantages are also detailed below, along with the attached examples. This is also clear from the explanation. [Modes for carrying out the invention]

[0035] In the first aspect, the present invention is - At least one avenanthramide or analog thereof, or at least one a Oat extract containing benanthramide or its analogues; and - A small number of agents selected from the group consisting of chelating agents, organic acids, antioxidants, and mixtures thereof. at least one type of stabilizer This relates to compositions containing or consisting of these.

[0036] The first main component of the composition according to the first aspect of the present invention is at least one avenant. Mid or its analogues, or at least one avenanthramide or its analogues It is an oat extract containing [ingredient].

[0037] The phrase "at least one" is used in this record, for example, in the context of Abenance. It can contain one or more avenanthramides among the lamidophores. It means a composition or oat extract. Furthermore, the phrase "at least one" means When applied to a list, it means any one combination of items identified within the list. ru.

[0038] A composition according to a first aspect of the present invention is a specified composition described in more detail below. It is prepared by combining the components.

[0039] In the context of the present invention, the term "avenanthramide" (anthranilic acid amide) means Members of the phenolic alkaloid group, namely mainly oats (Avena sativa). Although found in iva, the mons Butterfly eggs (Pieris brassicae and P. rapae) and fungi Infected carnations (also present in Dianthus caryophyllus) Spontaneously occurring avenanthramides, or those described in more detail below in this specification. It is thought to mean an artificially produced avenanthramide analog that does not occur naturally. ru.

[0040] The avenanthramide of the composition of the present invention is naturally found, isolated and purified from oats. It is possible. The two main species of oats are Avena sativa L. and Avena nuda L. (Synonyms include Gillet and Magne) Avena sativa subsp.nuda(L.) and Avena sativa subsp.nuda(L.) by Koern Ena sativa var. nuda (L.) is one example. A. sativa is It is also known as oats or oats in the shell. A. nuda is harvested with the shells on. Since it is removed at that point, it is known as naked oats or oats with the hulls removed. Oats can be processed and separated into a constituent fraction containing oat grains. Abenanthramide appears to be most concentrated in the peripheral regions, shells, trichomes, or straw. It appears that more than 50 distinctly different avenanthramides have been isolated from oat grains. [Collins, Journal of Agricultural and Food Chemistry, Vol. 37 (1989), pp. 60-66.

[0041] Avns can be expressed by the following general formula 1: [ka]

[0042] Table 1 below shows an example of spontaneously occurring Avns based on general formula 1.

[0043] [Table 1]

[0044] Several studies have shown that these natural products have anti-inflammatory, antioxidant, anti-itch, anti-irritant, and anti-inflammatory properties. It has been demonstrated that it possesses atherogenic activity.

[0045] Spontaneously occurring avenanthramides or a mixture of avenanthramides as described above The substance is extracted from plants of the genus Avena, especially any oat species, fresh or dried. or a part thereof, for example, Avena sativa species or Avena nud Obtained from ground grain, unground grain, hulls, trichomes, or oat straw of type a. It can be enriched and isolated.

[0046] The extraction solvent (extractant) for advantageously extracting avenanthramide L is a mixture of water and an organic solvent. Selected from the group consisting of compounds, the organic solvent is preferably a food product, cosmetic product, or pharmaceutical product. It is a solvent suitable for the product. Needless to say, such solvents are used in food, cosmetics, or pharmaceuticals. It must be appropriate and compatible with the preparation of the compound.

[0047] In a more preferred variation, the extraction solvent includes a mixture of water and alcohol or acetone. The alcohol is preferably methanol, ethanol, n-propanol, or isopropanol. n-butanol, isobutanol, t-butanol and mixtures thereof, i.e., combinations of these Selected from the group consisting of combinations. The most preferred extraction solvent for the extraction step of the present invention ( The extractants are methanol, ethanol, n-propanol, isopropanol, or acetate. Tons, or any combination of the aforementioned solvents, each mixed with water. It is a substance. The use of pure organic solvents is not advantageous due to the simultaneous extraction of triglycerides.

[0048] The mixing ratio of water to organic solvent in the extraction solvent, preferably the ratio of water to alcohol. The combined ratio or the mixing ratio of water to acetone is, in either case, relative to the resulting extraction solvent. The ratio is in the range of 10:90 to 90:10 (v / v), preferably 20:80 to 80:20. The range is (v / v), and most preferably it is in the range of 30:70 to 70:30 (v / v). ru.

[0049] Particularly preferred extraction solvents (extractants) are methanol / water (3:7) and methanol / water (1 :1), methanol / water (7:3), ethanol / water (3:7), ethanol / water (1: 1) Ethanol / water (1:4), Ethanol / water (7:3), Isopropanol / water ( 3:7), Isopropanol / Water (1:1), Isopropanol / Water (7:3), Acetate The ratios are acetone / water (3:7), acetone / water (1:1), and acetone / water (7:3).

[0050] To improve the extraction yield, the oat source should be heated to 30-80°C, preferably 40-70°C. Extraction is performed at a temperature in the range of °C, more preferably 50-60°C. In contrast, the extraction yield increases as the temperature increases between 40 and 70°C.

[0051] Apart from avenanthramide compounds enriched, isolated, and purified from natural sources, Naturally occurring avenanthramides can be produced by organic synthesis. The method of synthesis is, for example, U.S. Patent No. 6,096,770 and U.S. Patent No. 6,127 , Patent No. 392, Japanese Patent No. J60019754A and Hungarian Patent No. HU20099 This is illustrated in issue 6B.

[0052] The prepared synthetic avenanthramide substance is obtained by isolating or extracting the corresponding substance from oats. It is identical to naturally occurring avenanthramide compounds.

[0053] Equation 2 below: [ka] (wherein the formula m=0, 1, 2 or 3, p=0, 1 or 2, n=0, 1 or 2, However, if n=1 or 2, then p+m>0, If n=1 or 2, R 1 and R 2 In each pair, H is represented Alternatively, it may represent another chemical bond together (for example, as a cinnamic acid derivative), When m=1, 2, or 3, each X independently contains OH, Oalkyl, or Oacyl To express, When p=1 or 2, each Y independently represents OH, Oalkyl, or Oacyl. , If p+m>0, then at least one of X and Y is derived from OH and O acyl. The condition is that it is selected from the group, R 3 This refers to -H or alkyl (especially -CH3, or other straight elements having 2 to 30 C atoms). A chain or branched alkyl chain, and in this context, R 3 Also, the corresponding pharmaceutically permissible (Also -H for the salt that is tolerated) This is a compound that possesses important biological properties, and is referred to herein as "similar" below. In the composition according to the present invention, also called "avenanthramide compound" or "analogous avenanthramide compound," Unnaturally occurring avenanthramide analogs include, for example, WO2004 / 047833A1. Alternatively, it can be artificially produced using the organic synthesis method described in WO2007 / 062957A1.

[0054] Particularly preferred compounds of formula 2 according to the present invention are: n=1 or 2, p+m>0, and / or p+m>0, and at least one of X or Y or X and Y is OH and O It is a compound selected from the group consisting of alkyl groups.

[0055] Particularly preferable are n=1 and p+m>2, where at least one of X and Y Formula 2 is defined as having two elements that are selected together from the group containing OH and Oalkyl groups. Compounds are used.

[0056] n=1, m=1, 2, or 3, where at least one X is OH and Selected from the group containing Oalkyls, and / or subject to the condition that P=1 or 2. Furthermore, the condition is that at least one Y is selected from the group containing OH and Oalkyl. It is also preferable to use the compound of formula 2.

[0057] If n has a value of 1, R 1 and R 2 Each of them is preferably H, however R 1 and R 2 It is also possible for these to combine to form a different chemical bond.

[0058] Formula 2 and WO2004 / 047833A1 or WO2007 / 062957A1 Regarding the definition of specific avenanthramide compounds disclosed, the corresponding opening in the aforementioned document The references are incorporated herein by reference.

[0059] The avenanthramide analog compound of formula 2 is preferably, [ka] [ka] [ka] [ka] It is selected from the group consisting of the following.

[0060] The above example is essentially relating to the compound of Equation 2 where n=1.

[0061] However, the use of the compound of Equation 2 where n=0 is also often preferred, in which case m+ p=0, or m+p>1 or 2, where of substituents X and Y The condition is that at least two of them are selected from the group containing OH and Oalkyl. It is preferable.

[0062] [ka] [Chemical formula] [Chemical formula] It is particularly preferred to use a compound of formula 2 (n = 0) selected from the group comprising.

[0063] Particularly preferred is described, and in the compounds represented by these structural formulas, R 3 is always H there is.

[0064] Instead of these preferred compounds, in each case, R 3 is CH3, or it is also preferred to use the corresponding compound which is a linear or branched alkyl having 2 to 30 C atoms.

[0065] From the above avenanthramide analog compounds, compound number 8 (dihydroavenanthramide D ) is particularly preferred.

[0066] In addition to the above naturally occurring avenanthramides and non-naturally occurring avenanthramide analogs , N-(4'-hydroxycinnamoyl)-3-hydroxyanthranilic acid (YAvn I) and N-(3'-4'-dihydroxycinnamoyl)-3-hydroxyanthranilic acid (YAvn II), novel avenanthramide analogs are produced in recombinant yeast and these encode the major proteins involved in the biosynthesis of phenolic esters Two plant genes (4cl-2 from tobacco and hc t from artichoke) are used to engineer the Saccharomyces cerevisiae strain It was generated by doing so. Notably, YAVn I and YAVn II are A It shares structural similarities with vn A and Avn C, respectively.

[0067] In the context of the present invention, naturally occurring avenanthramides obtained from natural sources or synthetically produced avenanthramides. Avenanthramide is preferred and used similarly.

[0068] The term "avenance thramide or its analogues" refers to the various isomers of these existing products. In particular, naturally occurring trans-isomers and cis-isomers, for example, when exposed to light Photoisomerization induced a cis-isomerized double bond (formula 1 or 2 having n=1) It has one or two cis-isomerized double bonds (formula 1 or 2 with n=2). This is intended to include avenanthramides as well.

[0069] In particular, within the context of the present invention, avenanthramide is represented by general formula 1 and is defined in Table 1. It is any one of the avenanthramide compounds, or any isomer thereof. The avenanthramide analog is the avenanthramide analog represented by general formula 2 and its definition. The compound or any one of its isomers as described above. ru.

[0070] In a preferred variation of the present invention according to the first aspect, the composition comprises avenanthramide A, B, A selection from the group consisting of C, G, H, K, L, and R, more preferably an avenan. At least one avenant thramide selected from the group consisting of thramides A, B, C, or L. Includes "do".

[0071] In another variant, the composition is avenanthramide A, B, C, G, H, K, L (non-choline). Abbreviations for Z; CAS number 172549-38-1) (also known as O or 2pd) and R Two, three, four, or even more avenations are selected from the group consisting of It contains a mixture of lamids. The mixture of avenant lamides is therefore the following of avenant lamides The combination can contain any one of the following: A / B; A / C; A / G; A / H; A / K;A / L;A / R;B / C;B / G;B / H;B / K;B / L;B / R;C / G;C / H;C / K;C / L;C / R;G / H;G / K;G / L;G / R;H / K;H / L;H / R;K / L;K / R;and L / R;A / B / C;A / B / G;A / B / H;A / B / K;A / B / L;A / B / R;A / C / G;A / C / H;A / C / K;A / C / L;A / C / R;A / G / H;A / G / K;A / G / L;A / G / R;A / H / K;A / H / L; A / H / R;A / K / L;A / K / R;A / L / R;B / C / G;B / C / H;B / C / K, B / C / L;B / C / R;C / G / H;C / G / K,C / G / L;C / G / R,G / H / K;G / H / L;G / H / R;H / K / L, H / K / R;K / L / R;A / B / C / G;A / B / C / H;A / B / C / K;A / B / C / L;A / B / C / R;A / C / G / H;A / C / G / K;A / C / G / L;A / C / G / R;A / G / H / K;A / G / H / L;A / G / H / R;A / H / K / L;A / H / K / R;A / K / L / R;B / C / G / H;B / C / G / K;B / C / G / L;B / C / G / R;C / G / H / K;C / G / H / L;C / G / H / R;G / H / K / L;G / H / K / R and H / K / L / R.

[0072] However, the most preferred mixtures of avenanthramide are A / B, A / C, A / L, B / C. These are B / L, A / B / C, A / B / L, or A / C / L.

[0073] In addition, the composition also contains avenanthramides A, B, C, G, H, K, L (non-Collins abbreviated). Word; CAS number 172549-38-1) (also called O or 2pd) and other than R avenanthramides, for example, avenanthramide D, E, FU, X, Y (also known as 2) ), AA, CC, OO, or any of the remaining avenanthramide compounds in Table 1 It can include...

[0074] In another variant, the composition of the present invention contains avenanthramide A, B, C, G, H, K, L( Non-Collins abbreviation; CAS number 172549-38-1) (also known as O or 2pd) and at least one selected from the group consisting of R, i.e., one, two or more More avenanthramides are obtained from the avenanthramide analog compound represented by formula 8 above. It contains the substance dihydroavennanthramide D in combination with avenanthramide mixtures. It may contain one of the following: A / dihydroavennanthramide D; B / Dihydroavennanthramide D; C / Dihydroavennanthramide D; G / Dihydroave Nanthramide D;H / Dihydroavennanthramide D;K / Dihydroavennanthramide D; L / dihydroavennanthramide D; or R / dihydroavennanthramide D; A / B / di Hydroavennanthramide D;A / C / Dihydroavennanthramide D;A / D / Dihydro Benanthramide D;A / G / Dihydroavennanthramide D;A / H / Dihydroavennanthramide Lamide D; A / K / Dihydroavennanthramide D; A / L / Dihydroavennanthramide D ;A / R / Dihydroavennanthramide D;B / C / Dihydroavennanthramide D;B / D / Dihydroavennanthramide D;B / G / Dihydroavennanthramide D;B / H / Dihydro Roavenanthramide D;B / K / Dihydroavenanthramide D;B / L / Dihydroavena Nsulamide D;B / R / dihydroavennanthramide D;C / D / dihydroavennanthramide D;C / G / Dihydroavennanthramide D;C / H / Dihydroavennanthramide D;C / K / dihydroavennanthramide D;C / L / dihydroavennanthramide D;C / R / di Hydroavennanthramide D;G / H / Dihydroavennanthramide D;G / K / Dihydro Benanthramide D;G / L / Dihydroavennanthramide D;G / R / Dihydroavennanthramide Lamide D; H / K / dihydroavennanthramide D; H / L / dihydroavennanthramide D ;H / R / dihydroavennanthramide D;K / L / dihydroavennanthramide D;K / R / Dihydroavennanthramide D; or a combination of L / R / dihydroavennanthramide D. More preferably, A / dihydroavennanthramide D or avenanthramide L / di It may contain hydroavenanthramide D.

[0075] In addition to the above avenanthramide combinations, the composition includes avenanthramides A, B, C, and G. H, K, L (Non-Collins abbreviations; CAS number 172549-38-1) (O or 2pd and (also called) and one or more avenanthramides other than R, for example, avenanthramide Mido D, E, FU, X, Y (also called 2), AA, CC, or OO, or specified in Table 1. One of the remaining avenanthramide compounds and dihydroavennanthramide D This can further include combinations with the following.

[0076] In yet another variant, the composition of the present invention is dihydroavenanthramide D(2-{[ 3-(4-hydroxyphenyl)propanoyl]aminobenzoic acid; INCI name: Hydro Xyphenylpropamide benzoic acid (CAS 697235-49-7) or dihydroabe Nanthramide D and the compounds represented by general formula 1 and specified in Table 1 above Any one or more different avenanthramides or those represented by general formula 2, as defined above This includes combinations with identified avenanthramide analog compounds.

[0077] Spontaneously occurring avenanthramide compounds or non-spontaneously occurring avenanthramide analog compounds Instead, the present invention's composition is an oat extract containing at least one avenanthramide. It may include: In the context of the present invention, the term "oat extract" is generally used to mean: It is intended to include compounds or mixtures of compounds obtained from oats by extraction. ru.

[0078] Avenance containing at least one avenanthramide or an avenance as described above Such extracts containing a mixture of lamids may contain water, alcohol, acetone, or these. Extraction using a mixture of (e.g., maceration, leaching, extraction using Soxhlet, micro) Subcritical fluids (by waves or ultrasound) or using these solvents or mixtures thereof These are obtained by extraction. These are preferably obtained using various solvent compositions, such as pure methanol. Ethanol, n-propanol, isopropanol, n-butanol, isobutanol t-butanol and mixtures, i.e., combinations thereof, or mixtures with water, the same Extraction is performed using a solvent. This can be done at room temperature or under controlled heating over different periods of time, for example. The extraction procedure was achieved using naked oats, 50% aqueous ethanol, etc. ng L. et al., Journal of Integrative Agriculture e, 2014, Vol. 13, p. 1809]. Maliarova, M. et al., Journa l of the Brazilian Chemical Society, 2015 Volume 26 (Issue 11), pages 2369-2378, Avn from Naked Oats The efficiency of methanol, ethanol, and isopropanol was compared for the extraction of s. The optimal conditions for the highest yield of Avns are a methanol concentration of 70% and an extraction temperature of 55°C. The extraction time is 165 minutes.

[0079] The extract is from plants of the genus Avena, especially any oat species, fresh or dried, or that part, for example, crushed grain, uncrushed grain, hull, trichome or From the oat straw of the oat species Avena sativa or Avena nuda It is obtained. The starting product for extraction is oat grain residue obtained from oat oil production. It is possible.

[0080] In a preferred variant, the starting material for oat extract is Avena sativa. Seeds or Avena nuda seeds or crushed or uncrushed oat straw It is a grain.

[0081] Advantageous extraction of avenanthramide L and naturally occurring avenanthramide analog compounds. The extraction solvent (extractant) is selected from the group consisting of a mixture of water and an organic solvent, and the organic solvent is Preferably, it is a solvent suitable for food products, cosmetics, or pharmaceutical preparations. Needless to say, Such solvents are suitable for the preparation of food, cosmetic, or pharmaceutical preparations, and are compatible. Sex is essential.

[0082] In a more preferred variation, the extraction solvent includes a mixture of water and alcohol or acetone. The alcohol is preferably methanol, ethanol, n-propanol, or isopropanol. L, n-butanol, isobutanol, t-butanol and mixtures, i.e., these Selected from a group consisting of combinations. The most preferred extraction solvent for the extraction step of the present invention. (Extractants) are methanol, ethanol, n-propanol, isopropanol or acetate Each combination of tons or any mixture of the aforementioned solvent, each a mixture with water. The use of pure organic solvents is not advantageous due to the simultaneous extraction of triglycerides.

[0083] In the extraction solvent, water, in an organic solvent, preferably water in an alcohol or water The mixing ratio of acetone to the generated extraction solvent is 10:90-90: The range is 10(v / v), preferably in the range of 20:80 to 80:20(v / v). The most preferred range is 30:70 to 70:30 (v / v).

[0084] Particularly preferred extraction solvents (extractants) are methanol / water (3:7) and methanol / water (1 :1), methanol / water (7:3), ethanol / water (3:7), ethanol / water (1: 1) Ethanol / water (1:4), Ethanol / water (7:3), Isopropanol / water ( 3:7), Isopropanol / Water (1:1), Isopropanol / Water (7:3), Acetate The ratios are acetone / water (3:7), acetone / water (1:1), and acetone / water (7:3).

[0085] From the aforementioned extraction mixture (extractant), methanol / water (1:1), methanol / water (7:3 ), ethanol / water (1:1), ethanol / water (1:4), isopropanol / water (3 7), Isopropanol / Water (1:1), Isopropanol / Water (7:3), Acetone Acetone / water (3:7), acetone / water (1:1), and acetone / water (7:3) are particularly favorable. This is because extraction using these extractants results in a high avenanthramide L content (see Table 10). This is because it results in an extract having (see reference). The yield of benanthramide L is >150 ppm, more preferably >190 ppm. Most preferably, it is >200 ppm.

[0086] To improve the extraction yield, the oat source should be at 30-80°C, preferably 40-70°C. Extracted at a temperature in the range of 50-60°C. Ground oat grains. The extraction yield for increases with increasing temperature between 40 and 70°C. Extraction from oak is performed at a temperature between 50 and 60°C, yielding a good amount of avenanthramide. It yields the best results in terms of quantity, especially avenanthramide L content, therefore preferable.

[0087] Modifying the solvent composition will affect the avenanthramide substance that will be extracted, and therefore the composition. By altering the extraction selectivity of a substance, its biological activity can be enhanced or reduced. Cut.

[0088] The oat extract of the composition according to the first aspect of the present invention contains avenanthramide A, B, C, G, H, K, L (Non-Collins abbreviations; CAS number 172549-38-1) (O or 2p) At least one avenanthramide selected from the group consisting of (also called d) and R Includes.

[0089] In another variant, oat extract contains avenanthramide A, B, C, G, H, K, L ( Non-Collins abbreviation; CAS number 172549-38-1) (also known as O or 2pd) Two, three, four or more AVEs selected from the group consisting of R and It contains a mixture of avenanthramides. Therefore, the mixture of avenanthramides is avenanthramides The following combinations are possible: A / B; A / C; A / G; A / H; A / K ;A / L;A / R;B / C;B / G;B / H;B / K;B / L;B / R;C / G;C / H ;C / K;C / L;C / R;G / H;G / K;G / L;G / R;H / K;H / L;H / R ;K / L;K / R;and L / R;A / B / C;A / B / G;A / B / H;A / B / K; A / B / L;A / B / R;A / C / G;A / C / H;A / C / K;A / C / L;A / C / R;A / G / H;A / G / K;A / G / L;A / G / R;A / H / K;A / H / L;A / H / R;A / K / L;A / K / R;A / L / R;B / C / G;B / C / H;B / C / K, B / C / L;B / C / R;C / G / H;C / G / K, C / G / L;C / G / R, G / H / K;G / H / L;G / H / R;H / K / L, H / K / R;K / L / R;A / B / C / G; A / B / C / H;A / B / C / K;A / B / C / L;A / B / C / R;A / C / G / H; A / C / G / K;A / C / G / L;A / C / G / R;A / G / H / K;A / G / H / L; A / G / H / R;A / H / K / L;A / H / K / R;A / K / L / R;B / C / G / H; B / C / G / K;B / C / G / L;B / C / G / R;C / G / H / K;C / G / H / L; C / G / H / R; G / H / K / L; G / H / K / R and H / K / L / R.

[0090] However, the most preferred mixtures of avenanthramide are A / B, A / C, A / L, B / C, These are B / L, A / B / C, A / B / L, or A / C / L.

[0091] In addition, oat extract also contains avenanthramide A, which occurs naturally in oats. , B, C, G, H, K, L (non-Collins abbreviation; CAS number 172549-38-1) (O (Also known as 2pd) and avenanthramides other than R, e.g., avenanthramide D, E, FU, X, Y (also called 2), AA, CC, or OO, or the rest of Table 1 avenanthramide compounds or avenanthramide analogs according to Formula 2 specified above It can contain either of the following:

[0092] In addition, oat extract also contains at least one species of Avena according to Formula 2 identified above. The material may further contain nslamide analog compounds, particularly dihydroavennanceramide D.

[0093] At least one type of avenanthramide or avenanthramide as described above. Avenanthramide or avenanthramide (avenenthr A mixture of amide analog compounds is present in the composition or oat extract, by the total weight of the composition. It may be present in concentrations or total amounts ranging from 0.0001 to 5.0% by weight, depending on the quantity. Preferred variant Therefore, the composition or oat extract contains at least one avenanthramide or ave Nanthramide analog compounds or avenanthramide or avenanthramide analog compounds A mixture of substances, based on the total weight of the composition, at a concentration or total amount of 0.0005 to 2.0% by weight. More preferably, it is included in a concentration or total amount of 0.001 to 1.0% by weight.

[0094] The second main component of the formulation according to the first aspect of the present invention is at least one stabilizer. At the very least, one type of stabilizer consists of chelating agents, organic acids, antioxidants, and mixtures thereof. Selected from.

[0095] In the context of this invention, the term "at least one stabilizer" means any one of the stabilizers. The agent alone or more than one type of stabilizer, i.e., two types, or even more than that, In other words, a combination of stabilizers from one stabilizer category or different stabilizer categories. It is intended to include a combination of stabilizers from.

[0096] In the context of this invention, the stabilizer decomposes the active component of the composition, namely avenanthramide. To block or reduce, and thus affect other components of the composition or final product in which they are used. These are chemical compounds used to extend the shelf life of a substance without affecting its overall health.

[0097] Surprisingly, a group consisting of chelating agents, organic acids, antioxidants, and any mixture thereof... Combining avenanthramide with at least one stabilizer selected from the above is important for its stability. Or avenanthramide or more avenanthramide It has been found to be beneficial in improving the stability of compositions containing lamids. In particular, Adding one of the stabilizers significantly inhibits the degradation of one of the avenanthramides. Even more surprisingly, the addition of one of the stabilizers according to the present invention is the most concerning among avenanthramides. It is particularly effective in stabilizing the avenanthramide compound avenanthramide C. It has been found that...

[0098] Chelating agents are substances that form covalent coordination compounds with metal ions or metal atoms. Yes, these groups of molecules or atoms surround the central ion or atom of the metal, so-called As a Lewis acid, it donates all electron pairs to a bond, and therefore acts as a catalyst otherwise. It inactivates trace amounts of metal ions. Chelating agents are also called ligands, and the complex is chelated. It is formed in this way.

[0099] In addition to their metal chelating properties, chelating agents also enhance antioxidant and preservative effects. It possesses. Metal ions react with oxygen to form groups and other reactions that can result in discoloration and odor. It may form seeds. In peroxide formulations, metal ions react with peroxides, It causes the decomposition of oxides and the formation of new groups. Furthermore, chelating agents enhance the activity of biocides. Therefore, it was found that it becomes possible to use significantly lower levels of biocides.

[0100] By sequestering undesirable metal ions, chelating agents are a cause of water hardness. This prevents the precipitation of salts and protects against rancidity or discoloration caused by heavy metals. This is possible. Therefore, the bonding of metal atoms stabilizes the odor, structure, and color of the finished preparation. This process increases the stability and storage life of the composition or final formulation. To grant a lifespan.

[0101] In a preferred variant, the chelating agent used in the composition according to the first aspect of the present invention is EDTA or its sodium, calcium, or magnesium salts, phytic acid, Tetrasodium glutamate diacetate, trisodium ethylenediamine disuccinate, citric acid Sodium, potassium citrate, sodium phytate, sodium gluconate, gluconate Calcium phosphate, caprylhydroxamic acid, galactaric acid, galacturonic acid, metaphosphate Sodium, sodium polyitaconate, disodium etidronate, and methylglycerin It is selected from the group consisting of trisodium diacetate.

[0102] Phytic acid is a dihydrogen phosphate ester (specifically, myo-isomer) that is six times more abundant than inositol. Also known as inositol hexakisphosphate (IP6) or inositol It is a polyphosphate. Phytic acid and phytic salts are dietary mineral calcium. It has a strong binding affinity for iron and zinc, and inhibits their absorption.

[0103] As demonstrated in the following examples, the chelating agent specified above, EDTA or The salt, trisodium ethylenediamine disuccinate, or tetrasodium glutamate diacetate These are particularly preferred because they have especially good degradation inhibitory activity. Harmful activity means that, when used according to the present invention, even at low concentrations of these compounds, the desired activity is achieved. This means that inhibition occurs. EDTA, especially disodium EDTA, is the most effective single It is a chelating agent, and therefore most preferable as a stabilizer among chelating agents.

[0104] Furthermore, the stabilizer is an organic acid having 2 to 10 carbon atoms, preferably 3 to 8 carbon atoms. , can be characterized by a carboxyl (-COOH) functional group or gluconolactone . Among organic acids, alpha-hydroxy acids (AHAs) are preferred.

[0105] Alpha-hydroxy acids (AHAs) are a class of chemical compounds consisting of carboxylic acids substituted with a hydroxyl group on an adjacent carbon and can be either naturally occurring or synthetic . Their use in the cosmetics industry is well-known. They are often found in products that help reduce wrinkles, soften strong, distinct wrinkles, and improve the overall appearance and texture of the skin. They are also used as chemical peels . Sometimes AHAs are used in cosmetics for other purposes, such as to adjust the pH . Due to their acidity, alpha-hydroxy acids allow formulations to have lower levels of preservatives, which is particularly beneficial for skin related to dry, sensitive or damaged skin .

[0106] The alpha-hydroxy acids according to the first aspect of the present invention are gluconic acid, glyceric acid, gly colic acid, isocitric acid, lactic acid, malic acid, citric acid, mandelic acid, azelaic acid, ani sic acid, ectoin, ferulic acid, folic acid, levulinic acid, niacin, sebacic acid, salicylic acid, sorbic acid, tartaric acid, 2-hydroxybutyric acid (hydroxyaotanoic ac id), 2-hydroxydecanoic acid, mixtures of these or their salts and gluconolact tones selected from the group consisting of.

[0107] Furthermore, the present invention also encompasses derivatives of AHAs. Preferably, AHAs are these pharmaceutical It is used in the form of a single salt or a mixture thereof. Particularly preferred are monovalent or divalent salts. These are ammonium salts. Among salts, there are sodium salts, calcium salts, and magnesium salts. Alternatively, ammonium salts are most preferred.

[0108] Throughout this invention, the term "AHA" also refers to stereoisomers, i.e., R-enanes. Includes thiomeric, S-enantiomer, or racemic mixtures.

[0109] Among the alpha hydroxy acids identified above, those demonstrated in the following examples include Citric acid, lactic acid, malic acid, or tartaric acid are particularly preferred. This is because it has degradation inhibitory activity. Good degradation inhibitory activity means that, when used in accordance with the present invention, This means that even at low concentrations, the desired inhibition occurs. Malic acid Alternatively, tartaric acid is the most effective single alpha hydroxy acid, and therefore, alpha hydro Among xicans, it is most preferred as a stabilizer.

[0110] Furthermore, stabilizers can also be antioxidants. Antioxidants are those that contain oxygen, peroxides, and This invention relates to a substance that inhibits oxidation or reactions driven by free radicals. The antioxidant according to embodiment 1 is 4-hydroxyacetophenone (p-hydroxyacetophenone Non; INCI name hydroxyacetophenone, CAS 99-93-4), ascorbic acid , 6-Paradol, uric acid, butylhydroxytoluol (butylhydroxyto luol (BHT), butylhydroxyanisole (BHA), ascorbyl palmitate Ascorbyl phosphate and its salts, carnosine, sodium ascorbate, luthi N, tocopherol, tocopheryl acetate, ubiquinone, tropolone and allantoin Selected from the following group.

[0111] Among the antioxidants identified above, as demonstrated by the following examples, 4-H Droxyacetophenone and ascorbic acid are particularly preferred. This is because they are particularly good This is because it has good degradation inhibitory activity. Good degradation inhibitory activity means that when used in accordance with the present invention... This means that even at low concentrations, the desired inhibition will occur. Corbic acid is the most effective single antioxidant, and therefore, among antioxidants, it is used as a stabilizer. This is the most preferable option.

[0112] As demonstrated in the following examples, select from the three groups of stabilizers listed above. When one type of stabilizer is added, avenanthramide or one or more avenants It significantly enhances the stability of compositions containing slamide. In particular, one of the stabilizers identified above. Adding significantly inhibits the degradation of avenanthramide C in the composition according to the present invention.

[0113] Among the stabilizers identified above, EDTA disodium, ascorbic acid, and ethylenedioxide are particularly noteworthy. Trisodium aminedisuccinate, 6-paradol, and phytic acid are most preferred.

[0114] Surprisingly, the decomposition of avenanthramides, particularly avenanthramide C, is achieved by the present invention. The composition contains one stabilizer from each of the two different categories of stabilizers described above. A chelating agent, i.e., a chelating agent and an alpha hydroxy acid, or a chelating agent and an antioxidant, If it contains one stabilizer from each of the alpha hydroxy acid and antioxidants, it remains It can be further decreased or further inhibited.

[0115] In another variant, the degradation of avenanthramide, particularly avenanthramide C, still The composition according to the invention contains one stabilizer each from three different respective categories of the stabilizers described previously That is, a stabilizer of chelating agent + alpha-hydroxy acid + antioxidant When each category contains one stabilizer, it can be further decreased or further inhibited The preferred triple stabilizer combination is disodium EDTA + ascorbic acid + citric acid.

[0116] Therefore, a preferred variant of the composition according to the invention contains a combination of two or even more stabilizers.

[0117] When stabilizers are used in such combinations, as demonstrated in the following examples, The inhibition of degradation can be significantly increased compared to the use of one single stabilizer.

[0118] From the above combinations, the following combinations of stabilizer compounds are preferred: Disodium EDTA + ascorbic acid; Disodium EDTA + citric acid; Disodium EDTA + 4-hydroxyacetophenone; Disodium EDTA + lactic acid; Disodium EDTA + maleic acid; Disodium EDTA + tartaric acid; Disodium EDTA + phytic acid; Ascorbic acid + disodium EDTA; Ascorbic acid + 4-hydroxyacetophenone; Ascorbic acid + tetrasodium glutamate diacetate; Phytic acid + tetrasodium glutamate diacetate; Phytic acid + ascorbic acid; Phytic acid + disodium EDTA; Phytic acid + hydroxyacetophenone; Phytic acid + malic acid; 4-hydroxyacetophenone + disodium EDTA; 4-hydroxyacetophenone + ascorbic acid; 4-hydroxyacetophenone + phytic acid; 4-Hydroxyacetophenone + Tetrasodium glutamate diacetate; 4-Hydroxyacetophenone + Trisodium ethylenediaminedisuccinate; 6-Parador * +EDTA disodium; 6-Parador * +Citric acid; 6-Parador * +Ascorbic acid; 6-Parador * + Tetrasodium glutamate diacetate; Disodium EDTA + ascorbic acid + citric acid.

[0119] In preferred embodiments of the present invention, synergistic effects exist for the following stabilizer combinations: EDTA disodium + ascorbic acid; Disodium EDTA + 4-hydroxyacetonephenone; EDTA disodium + lactic acid; Disodium EDTA + maleic acid; Disodium EDTA + tartaric acid; EDTA disodium + citric acid Ascorbic acid + 4-hydroxyacetophenone; Ascorbic acid + tetrasodium glutamate diacetate; Ascorbic acid + phytic acid; Citric acid + tetrasodium glutamate diacetate Phytic acid + tetrasodium glutamate diacetate; Phytic acid + ascorbic acid; Phytic acid + disodium EDTA; Phytic acid + hydroxyacetophenone; Phytic acid + malic acid; 4-hydroxyacetophenone + disodium EDTA; 4-hydroxyacetophenone + ascorbic acid; 4-hydroxyacetophenone + phytic acid; 4-Hydroxyacetophenone + Tetrasodium glutamate diacetate; 4-Hydroxyacetophenone + Trisodium ethylenediaminedisuccinate. 6-Parador * +EDTA disodium; 6-Parador * +Citric acid; 6-Parador * +Ascorbic acid; 6-Parador * + Tetrasodium glutamate diacetate; Disodium EDTA + ascorbic acid + citric acid. *: 6-Parador (INCI name: Hydroxymethoxyhenyldecanone; CAS 2711) 3-22-0) is better soluble in aqueous solutions than dipropylene glycol (DP G) Preferably used as the intermediate solution (such as a blend of 6-pardol in DPG) The trademark name for this product is SymDecanox DPG ex Symrise.

[0120] As is clear from the following examples, stabilizers are effective even at low concentrations.

[0121] The total amount of stabilizers present in the composition according to the present invention is 0.02 to 0.02 based on the total weight of the composition. It can be between 0.5% by weight. In the preferred variation, the total concentration of stabilizers in the composition This is 0.01 to 0.5% by weight based on the total weight of the composition, and more preferably than this. The amount can be between 0.02% and 0.2% by weight, based on the total weight of the composition.

[0122] Adding one of the above single stabilizers or combinations of stabilizers may result in a lack of absorption. It significantly inhibits the degradation of one of the following: A, B, C, or L. Abenanceramide A, B, The stabilization modulation for C or L is preferably 5% to 94.2% in total. The range is 10% to 60%, and the modulation of stabilization, particularly for avenanthramide C, is... As demonstrated by the following application examples, the concentration of the stabilizer is preferably 5%~ The percentage is 94.2%, preferably in the range of 10% to 60%.

[0123] For example, the combination of EDTA disodium and citric acid is EDTA disodium and citric acid Compared to 42.9% for acid combinations, avenanthramide showed 28.6% degradation. Therefore, when used at 0.1%, the EDTA content is the same as when used alone at the same dose. It was more effective than thorium.

[0124] Furthermore, adding one of the above single stabilizers or combinations of stabilizers is, Abe It significantly inhibits the degradation of nanthramide analogs, particularly dihydroavenanthramide D.

[0125] In addition to the above-mentioned decomposition stability, at least one stability in the composition according to the first aspect of the present invention The agent reduces or even inhibits discoloration of the composition during storage, even at low concentrations. This effect is This is demonstrated in the application examples below. Existing stabilization methods using ascorbic acid have been effective for the final product, and This action is particularly relevant because it causes discoloration in emulsion preparations. The composition according to the present invention, which contains an oat extract having s and a stabilizer, is stabilizer-free. It was observed that the product was more stable against photo-induced degradation than the Avn-enriched product. This is particularly observable in terms of Avn C content.

[0126] As demonstrated in the following examples, select from the three groups of stabilizers described above. Adding one type of stabilizer is used, such as avenanthramide or one or more avenans. The color stability of compositions containing nanthramide is significantly enhanced. In particular, one of the above stabilizers is added. Adding this significantly inhibits the degradation of avenanthramide C in the composition according to the present invention. Enhanced stability is desired even when these compounds are used at low concentrations, as long as they are used in accordance with the present invention. This means that inhibition occurs.

[0127] Regarding stabilizers, as mentioned above, they can also be applied to color stability. Among the stabilizers identified above, EDTA disodium, hydroxyacetophenone, and Tetrasodium glutamate diacetate and 6-paradol are the most preferred monochromatic compounds in terms of color stability. It is the primary stabilizer.

[0128] Furthermore, the color stability of the composition according to the present invention is the same as the previously described stability of the composition according to the present invention. One stabilizer from each of the three different categories of agents, namely a chelating agent + alcohol Alpha-hydroxy acids, or chelating agents + antioxidants, or alpha-hydroxy acids + antioxidants If the agent contains one stabilizer from each category of stabilizers, the following examples are given: As demonstrated, further improvements are possible.

[0129] From the above combinations, the following combinations of stabilizers or stabilizer compounds are preferred in terms of color stability. Shii: Ascorbic acid; Citric acid; Lactic acid; Malic acid; Phytic acid; 4-Hydroxyacetophenone; SymDecanox DPG; Tetrasodium glutamate diacetate; Ethylenediamine disuccinate trisodium; EDTA disodium + ascorbic acid; Disodium EDTA + citrate; Disodium EDTA + 4-hydroxyacetonephenone; EDTA disodium + lactic acid; Disodium EDTA + maleic acid; Disodium EDTA + tartaric acid; Disodium EDTA + phytic acid; Ascorbic acid + disodium EDTA; Ascorbic acid + 4-hydroxyacetophenone; Ascorbic acid + tetrasodium glutamate diacetate; Ascorbic acid + trisodium ethylenediaminedisuccinate; Citric acid + tetrasodium glutamate diacetate; Phytic acid + tetrasodium glutamate diacetate; Phytic acid + Trisodium glutamate diacetate Phytic acid + ascorbic acid; Phytic acid + disodium EDTA; 4-hydroxyacetophenone + disodium EDTA; 4-hydroxyacetophenone + ascorbic acid; 4-Hydroxyacetophenone + Trisodium ethylenediaminedisuccinate; 6-Parador * +EDTA disodium; 6-Parador * +EDTA disodium; 6-Parador * +Citric acid; Disodium EDTA + ascorbic acid + citric acid.

[0130] In a preferred embodiment of the present invention, the chelating agent is combined with alpha-hydroxy acid. If used, or if the chelating agent is used in combination with an antioxidant, or When hydroxy acids are used in combination with antioxidants, a synergistic effect on color stability is observed. Even the fruit exists. Therefore, from the above combinations, the following combinations of stabilizer compounds are particularly preferable: Disodium EDTA + 4-hydroxyacetonephenone; EDTA disodium + lactic acid; EDTA disodium + citric acid Disodium EDTA + maleic acid; Disodium EDTA + tartaric acid; Ascorbic acid + disodium EDTA; Ascorbic acid + hydroxyacetophenone; Ascorbic acid + tetrasodium glutamate diacetate; Ascorbic acid + 6-Paradol; Citric acid + tetrasodium glutamate diacetate; Phytic acid + disodium EDTA; Phytic acid + trisodium ethylenediaminedisuccinate; Phytic acid + tetrasodium glutamate diacetate; 4-hydroxyacetophenone + disodium EDTA; 4-hydroxyacetophenone + ascorbic acid; 4-Hydroxyacetophenone + Trisodium ethylenediaminedisuccinate; 6-Parador * +EDTA disodium; 6-Parador * +Citric acid; Disodium EDTA + ascorbic acid + citric acid. *: 6-Parador (INCI name: Hydroxymethoxyhenyldecanone; CAS 2711) 3-22-0) is preferably dipropylene glycol due to its better solubility in aqueous solutions. Used as a solution in kohl (DPG) (such a breakdown of 6-pardol in DPG) The trademark name for this product is SymDecanox DPG ex Symrise.

[0131] As is clear from the following examples, the stabilizer can effectively stabilize the color even at low concentrations. Cut.

[0132] A particularly preferred mixture according to the present invention is one in which the composition is: - 0.0001 to 5.0% by weight of at least one avenanthramide or its equivalent Oat extract containing the body, or at least one avenanthramide or its analogue. and - 0.02 to 0.5% by weight of at least one stabilizer, It is a mixture containing or consisting of these.

[0133] The compositions according to the present invention, particularly preferred compositions, are characterized by low avenate It exhibits thramide (avenanthramdie) decomposition and high color stability. This invention... The stability and effectiveness of the composition are surprisingly good, with one or more avenanthramides It is superior to compositions containing only the substance active as a cosmetic or pharmaceutical, i.e. Abenanthramides have very interesting biological benefits, such as anti-inflammatory, antioxidant, and anti-inflammatory properties. It exhibits itching, anti-irritant, and anti-atheromatous activity, and therefore can be used for a longer period at therapeutically effective doses. It is capable of achieving these intended targets more effectively.

[0134] The compositions according to the present invention are also particularly effective in any toxicological or dermatologically serious It does not contain secondary components. Therefore, this composition is not a cosmetic or pharmaceutical preparation. It can be used without further concern.

[0135] Stabilizers used in the composition and final preparation in the concentration range relevant to activity and administration are , in the concentration range relevant to activity and administration, - Toxicologically acceptable, - Sufficiently tolerable to the skin, - Stable (especially in conventional formulations), - Preferably odorless, and - Can be produced cheaply (i.e., using standard processes, and / or (Starting from a standard precursor) Please keep that in mind.

[0136] Therefore, the compositions according to the present invention are for skin protection and for the prevention of skin diseases and / Alternatively, it is beneficial in this way in treatment.

[0137] Therefore, another aspect of the present invention is the composition according to the first aspect of the present invention as a cosmetic. Use, especially in skincare, scalp care, hair care, nail care, or skin conditions, Sensitive and delicate skin, skin irritation, skin redness, wheals, itching, skin aging, Formation of wrinkles, decrease in skin volume, loss of skin elasticity, pigment spots, pigment abnormalities, or dry skin, in other words, wrinkles Use as a cosmetic in the prevention and / or treatment of dry skin requiring skin moisturizing. Regarding.

[0138] Another aspect of the present invention relates to a composition according to the first aspect of the present invention for use as a pharmaceutical. do.

[0139] Due to the excellent properties described above, the formulation according to the first aspect of the present invention is effective for skin diseases or keratin Diseases, particularly those related to the barrier, such as inflammatory, immunoallergic, atherogenic, and dry conditions. or prevention of skin diseases or keratinized diseases having excessively proliferative components and / or In treatment, or for the prevention of cardiovascular disease, allergic reactions, coronary heart disease and / or In the treatment, to reduce serum LDL cholesterol and lipid levels To lower blood pressure, improve insulin sensitivity, and control blood glucose levels It is particularly useful in making this possible.

[0140] Due to the specific antioxidant properties of avenanthramide, this invention also addresses the increased ROS production associated with the present invention. A composition according to a first aspect of the present invention for use in the prevention and / or treatment of skin diseases It also relates to this.

[0141] Examples of such skin disorders include eczema, psoriasis, seborrhea, dermatitis, erythema, and pruritus (itching). Otitis, inflammation, irritation, fibrosis, lichen planus, pityriasis rosea, tinea versicolor, autoimmune bullous diseases urticaria-like, angiodermal, and allergic skin reactions Examples include response, wound healing, and / or skin diseases associated with increased ROS production. atopic dermatitis, neurodermatitis, psoriasis, rosacea, acneiform rash, xerosis and xerosis Selected from the following group.

[0142] A particularly preferred variant of the present invention contains at least one avenanthramide or a similar compound. The present invention comprises an analog or at least one avenanthramide or its analog. Compositions containing or comprising oat extract are for the prevention and / or treatment of pruritus (itching). It is useful in a way that is beneficial to the treatment.

[0143] Chronic pruritus is a common symptom associated with various skin conditions and systemic diseases, and in some cases Therefore, there is no underlying public knowledge. Chronic pruritus is characterized by clinical symptoms (e.g., affected / inflammated). Combined with the presence of sexual, or normal / non-inflammatory skin and / or secondary scratch lesions. (and) and underlying causes (e.g., skin disease, systemic, nervous system, psychosomatic, mixed or Classified by (the origin of uncertainty).

[0144] avenanthramide or its analogues or avenant for each of these purposes The use of oat extract containing thuramide or its analogues is effective in providing therapeutically effective amounts of the active substance or This is a method for imparting the therapeutic activity of each active substance by adding a composition. handle.

[0145] In the context of this invention, the effective amount of the composition refers to the amount of each active ingredient, i.e., the average amount. The amount of lamid, and the benefit, for example, the reduction of symptoms associated with the disorder, disease, or condition being treated. This is a sufficient amount to demonstrate when applied to a combination or composition, as in the present invention. This term refers to the amount of combined active ingredients that produce a benefit.

[0146] Therefore, the present invention relates to a condition that requires a skin disease or keratinous disease, and specifically Inflammation, immunoallergic, atherogenic, dry, or excessive barrier function. For the prevention and / or treatment of skin diseases or keratinized diseases having proliferative components. The method involves adding at least one avenanthramide or analog thereof to the target, oat extract containing at least one avenanthramide or analog thereof; and In skin diseases or keratinized disorders, especially those related to the barrier, such as inflammatory, immunoallergic, and atherosclerotic conditions. A precursor to skin diseases or keratinized diseases having components that are cyst-producing, drying, or excessively proliferating. Containing or comprising at least one stabilizer in an amount sufficient for prevention and / or treatment. The present invention relates to a method comprising administering a therapeutically effective amount of a composition.

[0147] Due to the remarkable effects described above, the composition according to the first aspect of the present invention It is beneficially suitable for the preparation of foods, nutritional supplements, cosmetics, pharmaceuticals, or veterinary preparations.

[0148] The composition according to the present invention is a conventional food, nutritional supplement, cosmetic, pharmaceutical or veterinary preparation. It can be easily integrated into [the system].

[0149] Therefore, further aspects of the present invention include foods and nutritional supplements containing the composition according to the present invention. The present invention relates to cosmetics, pharmaceuticals, or veterinary preparations. A preferred variation of the present invention comprises a composition. Functional foods may also be used for skincare and / or to prevent the above-mentioned skin disorders or keratinization disorders. It is provided as an active ingredient for recovery.

[0150] In preferred variations, foods, nutritional supplements, cosmetics, pharmaceuticals, or veterinary preparations are prepared A weight of 0.0001 to 10% of the total weight of the object, with a more preferable 0.0005 to 5%. The composition or oat extract according to the present invention is used in an amount of %, most preferably 0.001 to 1% by weight. This includes materials, which are obtained using the method according to the present invention.

[0151] In this context, the composition according to the present invention may be enhanced with other active compounds, such as other synergistically enhancing substances. For example, anti-inflammatory, antibacterial, or antifungal substances, or substances that reduce redness or itch. Substances with functional properties, analgesics, humectants and / or cooling agents and / or antioxidants , as a preservative, (metal) chelating agent, penetration enhancer, and / or as a cosmetic, or as a drug It is also possible to combine it with scientifically acceptable excipients, and in some cases, this may be advantageous. ru.

[0152] An active substance means a substance or compound that imparts a primary utility to a composition or formulation. Examples of such active substances include antioxidants, preservatives, (metal) chelating agents, and penetration enhancers. These are some examples. Excipients are substances that, as a result of processing or manufacturing, enhance the properties of cosmetics or pharmaceuticals. This refers to the inert substance used to formulate the drug.

[0153] Skin conditions or skin diseases often include dry skin, scratched skin, skin lesions or Furthermore, since inflammation is involved, cosmetics and / or pharmaceutical preparations are particularly advantageous in moisturizing the skin. and / or moisture-retaining substances, cooling agents, osmolite, keratolytic substances, nutrients, anti Inflammatory, antibacterial, or antifungal substances, and / or anti-redness or anti-itch effects. It contains substances that have an effect and / or analgesic substances.

[0154] Itching occurs with a certain intensity when the skin is dry. Skin moisturizing and / or hydration The use of retaining substances or modifiers in cosmetics and pharmaceutical preparations significantly relieves itching. Therefore, the cosmetic or pharmaceutical preparation according to the present invention may also be one or It can be particularly advantageously combined with multiple skin moisturizing and / or moisture-retaining substances or modifiers. Therefore, the cosmetic or pharmaceutical preparation according to the present invention is also advantageous in that it allows for the following: It may contain moisturizing and / or moisture-retaining substances or modifiers: sodium lactate Urea, urea, urea derivatives, alcohol, glycerol, diol, for example, propylene Recall, hexylene glycol, 1,2-pentanediol, 1,2-hexanediol Lu, 1,2-heptanediol, 1,2-octanediol, 1,2-nonanediol, 1,2-decanediol or a mixture of the diol, particularly 1,2-hexanediol A mixture of 1,2-octanediol, collagen, elastin or hyaluronic acid, Diacyl adipate, petrolatum, urocanic acid, lecithin, panthenol, phytant Liol, lycopene, (pseudo)ceramide, glycosphingolipid, cholesterol, f Itosterol, chitosan, chondroitin sulfate, lanolin, lanolin ester, amino Acids, alpha hydroxy acids (e.g., citric acid, lactic acid, malic acid), and their derivatives Monosaccharides, disaccharides and oligosaccharides, such as glucose, galactose, fructose, and manubrine. Northose, fructose and lactose, polysucrose, e.g., R-glucan, especially E 1,3-1,4-β-glucan derived from oak, alpha-hydroxy fatty acids, triterpene Acids, such as betulinic acid or ursolic acid, and algal extracts.

[0155] Depending on the substance, the concentration of the moisture retention modifier used is the minimum concentration for ready-to-use cosmetics or pharmaceuticals. The amount is between 0.1 and 10% (m / m) of the total weight of the final product, preferably between 0.5% and 10%. The percentage is between 5% (m / m). These data are particularly useful for diols that are likely to be used favorably. For example, hexylene glycol, 1,2-pentanediol, 1,2-hexanediol Lu, 1,2-octanediol and 1,2-decanediol, and 1,2-hexa This applies to mixtures of dandiol and 1,2-octanediol.

[0156] The use of cooling agents in cosmetics and pharmaceutical preparations can relieve itching. The preparations according to the invention are therefore particularly advantageous when combined with one or more cooling agents. This can be done. The following are some of the individual cooling agents preferred for use within the framework of the present invention. They are listed. Those skilled in the art can add many other cooling agents to this list. The listed cooling agents can also be used in combination with each other: l-menthol, d-menthol, racemic menthol, menthol glycerol acetal (trademark name: Fre Frescolat (registered trademark MGA), Menthyl lactate (trademark name: Frescolat (registered trademark) Trademark) ML; Menthyl lactate is preferably l-menthyl lactate, especially l-menthyl l-lacte (It is a substituted menthyl-3-carboxamide (for example, menthyl-3-carboxylic acid) N-ethylamide), 2-isopropyl-N-2,3-trimethylbutanamide, substituted Chlohexancarboxamide, 3-menthoxypropane e)-1,2-diol, 2-hydroxyethylmenthyl carbonate, 2-hydroxy Propylmenthyl carbonate, N-acetylglycine menthyl ester, isoprego Menthyl hydroxycarboxylic acid esters (e.g., menthyl 3-hydroxybutyrate) (t) monomenthyl succinate, 2-mercaptocyclodecanone, menthyl 2-pyrrolidine -5-onecarboxylate, 2,3-dihydroxy-p-menthane, 3,3,5-tri Methylcyclohexanone glycerol ketal, 3-menthyl-3,6-di- and tri Oxaalkanoates, 3-menthylmethoxyacetate, and ishirin.

[0157] Due to these specific synergistic effects, preferred cooling agents are l-menthol and d-menthol. Racemic menthol, menthol glycerol acetal (trademark name: Frescolat) (Registered Trademark) MGA), Menthyl lactate (preferably l-menthyl lactate, especially l-menthyl l) -Lactate (trademark name: Frescolat(registered trademark)ML)), substitution menthyl-3- Carboxamide (e.g., menthyl-3-carboxylic acid N-ethylamide), 2-isopropyl Pyr-N-2,3-trimethylbutanamide, substituted cyclohexanecarboxamide, 3- Menthoxypropane-1,2-diol, 2-hydroxyethylmenthyl carbonate, These are 2-hydroxypropylmenthyl carbonate and isopulegol.

[0158] Particularly preferred cooling agents are l-menthol, racemic menthol, and menthol. Acetal (trademark name: Frescolat (registered trademark) MGA), Menthyl lactate (preferred This refers to l-menthyl lactate, especially l-menthyl l-lactate (trademark name: Frescolat). (Registered Trademark) ML)), 3-mentoxypropane-1,2-diol, 2-hydroxy These are thylmenthyl carbonate and 2-hydroxypropylmenthyl carbonate.

[0159] A particularly preferred cooling agent is l-menthol, menthol glycerol acetal ( Trademark name: Frescolat (registered trademark) MGA) and menthyl lactate (preferably l- Menthyl lactate, especially l-menthyl l-lactate (trademark name: Frescolat (registered trademark) The standard is ML).

[0160] Depending on the substance, the concentration of the cooling agent used will vary depending on the final product of the ready-to-use cosmetic or pharmaceutical product. Preferably between 0.01 and 20% by weight of the total weight of the product, and particularly preferably between 0.1% and 20% by weight. It is between 5% by weight.

[0161] Cosmetics or pharmaceutical preparations containing the composition according to the present invention also contain one or more of the following: It can also be used together with osmolite. The osmolite that can be described here is Examples include sugar alcohols (myo-inositol, mannitol, sorbitol), and quaternary ammonium compounds. For example, taurine, choline, betaine, betaineglycine, ectoin, diglyceride Roll phosphate, phosphorylcholine or glycerophosphorylcholine, amino acids, e.g. For example, glutamine, glycine, alanine, glutamate, aspartate, or proline. phosphatidylcholine, phosphatidylinositol, inorganic phosphates, and the aforementioned compounds Polymers of substances, such as proteins, peptides, polyamino acids, and polyols, are included in this group. The substances from which they are derived are listed. All osmolites also possess skin moisturizing properties.

[0162] Preferably, the keratolytic substance is also combined with the composition or oat extract according to the present invention. It can be done. A large group of alpha hydroxy acids can be cited as keratolytic compounds. For example, salicylic acid is preferably used.

[0163] For example, for topical cosmetic or medical treatment of dry and / or itchy skin, In a cosmetic or pharmaceutical preparation containing the composition according to the present invention, a particularly high proportion of nutrients The substance is also particularly advantageous in reducing transepidermal water loss due to lipophilic components. In one preferred embodiment, the cosmetic or pharmaceutical preparation provides one or more nutrients. Refined animal and / or vegetable fats, as well as oils, such as olive oil, sunflower oil, etc. Soybean oil, palm oil, sesame oil, rapeseed oil, almond oil, borage oil, evening primrose oil Coconut oil, shea butter, jojoba oil, sperm whale oil, taro, beef tallow and lard, In addition, optional components that provide other nutrients, such as fats containing 8 to 30 carbon atoms. Contains aliphatic alcohols. The aliphatic alcohols used here are saturated or unsaturated. It can be either off-chain and linear or branched. The mixture according to the present invention and Nutrients that can be preferably combined with it also include ceramide in particular, ceramide is Here, we introduce N-acylsphingosine (sphingosine), which significantly improves the water retention capacity of the stratum corneum. Gosin fatty acid amides) or synthetic analogs of such lipids (so-called pseudo-ceramides); Phospholipids, such as soy lecithin, egg lecithin and cephalin; as well as petrolatum, It is understood to mean paraffin oil and silicone oil, the latter of which is particularly diamine. Alkyl- and alkylarylsiloxanes, for example, dimethylpolysiloxane and This includes methylphenylpolysiloxane and alkoxylated and quaternized derivatives thereof.

[0164] Cosmetics or pharmaceutical preparations containing the composition according to the present invention also possess other anti-inflammatory activities. This text may contain compounds or active compounds that exhibit anti-redness and anti-itch activity. Within the pulse, any anti-inflammatory active compound, as well as relieving redness and itching, and cosmetics and / or Alternatively, active compounds that are appropriate or conventional for use in skin diseases can be used. This includes anti-inflammatory active compounds used, as well as activators that relieve redness and / or itching. The compound contains corticosteroid-type steroidal anti-inflammatory substances, such as hydrocortisone. Dexamethasone, dexamethasone phosphate, methylprednisolone or cortisol This list can be expanded by adding other steroid anti-inflammatory drugs. It can be used. Nonsteroidal anti-inflammatory drugs, for example: oxicam, for example, piroxicam or tenoxine. Sicam; salicylate, e.g., aspirin, Disalcid®, Solp rin(registered trademark) or fendosal; acetic acid derivatives, e.g., diclofenac, fen Clofenac, indomethacin, sulindac, tolmetin, or clindanac; fenum Acids, for example, mefenamic acid, meclofenamic acid, flufenamic acid, or diflumic acid; pro Pionic acid derivatives, for example, ibuprofen, naproxen, benoxaprofen; or Pyrazoles, for example, phenylbutazone, oxyphenylbutazone, febrazone or Azapropazone can also be used. Alternatively, natural anti-inflammatory substances and Substances that relieve redness and / or itching may also be used. Plant extracts, special high-activity Using a plant extract fraction, and furthermore, extremely pure active substances isolated from the plant extract. It can be done with chamomile, aloe vera, Commiphora species, Rubia species, and willow. Willow flower, ginger, marigold, arnica, licorice seeds, Echinacea seeds, Extracts, fractions, and active substances derived from Rubus species and pure substances, for example, among others, bisac Borol, apigenin, apigenin-7-glucoside, gingerol, e.g., [6]- Gingerol, paradol, e.g., [6]-paradol, boswellic acid, phytosterol Glycyrrhizin, glabridin, or licochalcohol A is particularly preferred. Preparations containing histamine-releasing inhibitors also contain two or more anti-inflammatory agents. It may contain a mixture of sexually active compounds.

[0165] Cosmetics or pharmaceutical preparations containing the composition according to the present invention also have an active ingredient for preservation purposes. It may contain compounds suitable or conventional for use in cosmetics and / or for skin diseases. And advantageously, for example, benzoic acid, its esters and salts; propionic acid and Salicylic acid and its salts; 2,4-hexanoic acid (sorbic acid) and its salts; Formaldehyde and paraformaldehyde; 2-hydroxybiphenyl ether and Biso salts; 2-zinc sulfidopyridine N-oxide; inorganic sulfites and bisulfites Sodium iodate; chlorobutanol; 4-hydroxybenzoic acid and its salts and Ester; dehydroacetic acid; formic acid; 1,6-bis(4-amidino-2-bromophenoxy) -n-Hexane and its salts; sodium salts of ethylmercury-(II)-thiosalicylic acid; Phenylmercury and its salts; 10-Undecylenic acid and its salts; 5-Amino-1,3- Bis(2-ethylhexyl)-5-methylhexahydropyrimidine; 5-bromo-5-ni Toro-1,3-dioxane; 2-bromo-2-nitro-1,3-propanediol; 2, 4-Dichlorobenzyl alcohol; N-(4-chlorophenyl)-N'-(3,4-dichlorophenyl) Lolophenyl)urea; 4-chloro-m-cresol; 2,4,4'-trichloro-2' -Hydroxy-diphenyl ether; 4-chloro-3,5-dimethylphenol; 1,1 '-Methylene-bis(3-(1-hydroxymethyl-2,4-dioxyimidazolidin- 5-yl)urea; poly(hexamethylene biguanide) hydrochloride; 2-phenoxyethanol Nol; Hexamethylenetetramine; 1-(3-chloroallyl)-3,5,7-triaza -1-Azonia adamantan chloride; 1-(4-chlorophenoxy)-1(1H- Midazole-1-yl)-3,3-dimethyl-2-butanone; 1,3-bis(hydroxy Methyl)-5,5-dimethyl-2,4-imidazolidinedione; benzyl alcohol; O ctopirox(registered trademark); 1,2-dibromo-2,4-dicyanovutane; 2,2' -Methylene-bis(6-bromo-4-chlorophenol);bromochlorophene;5- Chloro-2-methyl-3(2H)-isothiazolinone and 2-methyl-3(2H)iso A mixture of thiazolinone, magnesium chloride, and magnesium nitrate; 2-benzyl-4- Chlorophenol; 2-chloroacetamide; chlorhexidine; chlorhexidine acetate Chlorhexidine gluconate; Chlorhexidine hydrochloride; 1-Phenoxy-propane-2 -ol; N-alkyl(C12~C22)trimethylammonium bromide and chloro Lido; 4,4-dimethyl-1,3-oxazolidine; N-hydroxymethyl-N-(1, 3-Di(hydroxymethyl)-2,5-Dioxoimidazolidine-4-yl)-N'-H Droxymethylurea; 1,6-bis(4-amidinophenoxy)-n-hexane and The salt; glutaraldehyde 5-ethyl-1-aza-3,7-dioxabicyclo(3,3 0) Octane; 3-(4-chlorophenoxy)-1,2-propanediol; Hyami N; alkyl(C8~C18)dimethylbenzylammonium chloride; alkyl(C8 ~C18) Dimethylbenzylammonium bromide; Alkyl (C8~C18) Dimethylbenzylammonium bromide Benzylammonium saccharide; benzyl hemiformal; 3-iodo-2-propyl Nylbutylcarbamate; or sodium ((hydroxymethyl)amino)acetate Any preservative selected from the group consisting of such preservatives can be used.

[0166] Cosmetics or pharmaceuticals that also contain other antibacterial or antifungal active substances from the present invention. It can be used particularly advantageously in scientific preparations, and in cosmetics and / or for skin diseases. Any antibacterial or antifungal active substance that is appropriate or conventional for the purpose may be used. In addition to the broad group of conventional antibiotics, other products that are advantageous here include those related to cosmetics. For example, triclosan, crimbazole, octoxyglycerin, Octopi rox(registered trademark)(1-hydroxy-4-methyl-6-(2,4,4-trimethylpentine (Cyl)-2(1H)-pyridone 2-aminoethanol salt, chitosan, farnesol, Examples include glycerol monolaurate or combinations thereof, and these are particularly used in the armpits. It is used against body odor, foot odor, or dandruff.

[0167] The cosmetic and / or pharmaceutical preparations according to the present invention also contain one or more analgesic substances. It may contain and is appropriate or customary for use in cosmetics and / or pharmaceuticals. Analgesic substances of choice, such as alpha-bisabolol, azulene, guaiazulene, 18-β - Glycyrrhetinic acid, allantoin, aloe vera juice or gel, Hamameli Extract of witch hazel (Hamamelis virginiana), Echinacea species, Centel La asiatica, chamomile, ginger extract, gingerol, Arnica monatana, Glycyrrhiza species, algae, seaweed and Calendula o fficinalis, and vegetable oils, for example, sweet almond oil, baobab oil, etc. Leaf oil, panthenol, laureth-9, trideceth-9 and 4-t-butylcyclohexyl Xanol can be used.

[0168] In addition, cosmetics or pharmaceutical preparations also possess sweat-inhibiting activity to control body odor. It can be used particularly advantageously in combination with compounds (antiperspirants). (Used sweat inhibitors) Active compounds include aluminum salts, such as aluminum chloride, chlorohydrate, and nitrate. Examples include salts, sulfates, and acetates. However, zinc, magnesium, or zirconium The use of aluminum compounds can also be advantageous. Aluminum salts and, to a somewhat lower degree, However, the aluminum / zirconium salt combination is used in cosmetic antiperspirants and dermatological antiperspirants. It has been proven useful in [location]. Therefore, partially neutralized aluminum hydroxy It should also be noted that cyclolid is more tolerable to the skin, but less effective. It is. Other substances besides aluminum salts can also be used, for example, (a) sweat Protein precipitates that cause glandular surface sealing, such as formaldehyde, etc. (b) Lutaraldehyde, natural and synthetic tanning agents and trichloroacetic acid; (b) Local anesthetics The drug contains, for example, a dilute solution of lidocaine, prilocaine, or a mixture thereof, and is used in peripheral nerves By blocking the pathway, the sympathetic nerve supply to the sweat glands is switched off; (c) X, A or Y-type zeolites, these also act as a sweat-reducing agent and odor-adsorbing agent; (d) Botulinum toxin (toxin from the bacterium Chlostridium botulinum) It is also used in hyperhidrosis (pathological increase in sweat secretions), and its effects are related to sweat secretion. This is based on the irreversible blockage of the release of the neurotransmitter acetylcholine.

[0169] Combinations of (metal) chelating agents other than those described above used in the present invention Furthermore, this is advantageous in cosmetics or pharmaceutical preparations containing the composition according to the present invention. Any metal cutting tool that can be used and is suitable or customary for cosmetic and / or skin disease applications. A chelating agent can be used. A preferred (metal) chelating agent is α-hydroxylipid. Fatty acids, phytic acid, lactoferrin, as well as humic acid, bile acid, bile extract, bilirubin Examples include biliverdin or EGTA and their derivatives.

[0170] Preparations containing the composition according to the present invention are commonly used in cosmetics and dermatological products. Apply a sufficient amount to the skin, scalp, hair, and / or nails in a manner consistent with your usual routine. In this context, cosmetics containing the mixture according to the present invention and further acting as sunscreens Products and dermatological preparations offer specific advantages. Advantageously, these preparations offer at least One UVA filter and / or at least one UVB filter and / or It contains at least one inorganic pigment. In this context, the preparation is, for example, of this type. Preparations of, for example, solutions, water-in-oil (W / O) emulsions, oil-in-water (O / W) emulsions or multipliers. Chip emulsions, for example, water-in-oil-in-water (W / O / W) emulsions, gels, hydrodispersants, It can take various forms commonly used for solid sticks or aerosols. ru.

[0171] Preparations containing the composition according to the present invention include a substance that absorbs UV radiation in the UVB region and Advantageously, the total amount of filter material is, for example, 0 relative to the dry weight of the preparation. 0.01-40% (m / m), preferably 0.1-10% (m / m), particularly 1.0-5.0 A cosmetic preparation that protects hair and / or skin from UV radiation across the entire spectrum, with a % (m / m) protection factor. We can provide these products. These can also function as sunscreens for hair. It is possible. When the preparation according to the present invention contains UVB filter material, these are oil-soluble. It may be oil-soluble or water-soluble. The following are examples of advantageous oil-soluble UVB filters: Derived from: 3-benzylidene camphor derivatives, preferably 3-(4-methylbenzylidene) Camphor, 3-benzylidene camphor; 4-aminobenzoic acid derivative, preferably 2- Ethylhexyl 4-(dimethylamino)benzoate, Amyl 4-(dimethylamino)benzoate Cinnamic acid salts; cinnamic acid esters, preferably 2-ethylhexyl 4-methoxycinnamate, Isopentyl 4-methoxycinnamate; salicylic acid ester, preferably salicylic acid 2 -Ethylhexyl, 4-isopropylbenzyl salicylate, homomentyl salicylate; Derivatives of benzophenone, preferably 2-hydroxy-4-methoxybenzophenone, 2- Hydroxy-4-methoxy-4'-methylbenzophenone, 2,2'-dihydroxy-4 -Methoxybenzophenone; benzalmalonic acid ester, preferably di(2-ethylhexyl Sil)4-methoxybenzalmalonate, 2,4,6-trianilino-(p-carbo-2 '-ethyl-1'-hexyloxy)-1,3,5-triazine. Advantageous water-soluble UVB film As a filter, a salt of 2-phenylbenzimidazole-5-sulfonic acid, for example, Sodium salts, potassium salts or triethanolammonium salts, and sulfonic acid The substance itself; a sulfonic acid derivative of benzophenone, preferably 2-hydroxy-4-methoxy. Benzophenone-5-sulfonic acid and its salts; 3-benzylidene camphor sulfone Acid derivatives, for example, 4-(2-oxo-3-bornylidenemethyl)benzenesulfonic acid, 2-Methyl-5-(2-oxo-3-bornylidene-methyl)sulfonic acid and these Salt, and furthermore, 1,4-di(2-oxo-10-sulfo-3-bornylidenemethyl)-benze ¹ and its salts (corresponding 10-sulfate compounds, e.g., corresponding sodium, potassium) (Ammonium and triethanolammonium salts), and benzene-1,4-di(2-oxo -3-bornylidenemethyl-10-sulfonic acid is one example.

[0172] UVA filters, for example, UVA filters commonly found in cosmetic preparations, are used. This can be advantageous. These substances are preferably derivatives of dibenzoylmethane, particularly 1-(4'-tert-butylphenyl)-3-(4'-methoxyphenyl)propane- 1,3-dione and 1-phenyl-3-(4'-isopropylphenyl)propane-1 It is 3-dione. The amount used for UVB combinations can be similarly used. .

[0173] In cosmetics or pharmaceutical preparations, the compositions according to the present invention are also advantageous, for example, Other additives or excipients commonly used in such preparations, such as antioxidants, fragrances, and spices. Foaming agents, colorants, pigments with coloring properties, thickeners, surfactants, emulsifiers, plasticizers, moisture Other conventional moisturizing and / or water-retaining substances, fats, oils, waxes or cosmetic preparations The constituent materials include, for example, alcohols, polyols, polymers, foam stabilizers, electrolytes, organic solvents, etc. It can be combined with silicone derivatives. Cosmetic and / or skin disease applications. Any conceivable antioxidant, fragrance, defoamer, colorant, appropriate or conventional in the context of Pigments having coloring properties, thickeners, surfactants, emulsifiers, plasticizers, wetting agents and / or or moisture-retaining substances, fats, oils, waxes, alcohols, polyols, polymers, foam stabilizers Electrolytes, organic solvents, or silicone derivatives can be used here in accordance with the present invention. .

[0174] High concentrations of treatment substances are not suitable for topical, preventative, or cosmetic treatment of the skin. It is generally advantageous in preparations containing compositions according to the present invention. According to preferred embodiments, The product is a fat and oil derived from one or more animals and / or plants, for example, olives. Oils, sunflower oil, refined soybean oil, palm oil, sesame oil, rapeseed oil, almond oil, ru Ligosa oil, evening primrose oil, coconut oil, shea butter, jojoba oil, sperm whale oil, beef tallow, Beef tallow and lard, and optionally other treatment components, such as C8-C30 aliphatic oils. Contains alcohol. The aliphatic alcohols used herein may be saturated or unsaturated and These are linear or branched aliphatic alcohols, examples of which include decanol, decenol, and octa. Nol, Octenol, Dodecanol, Dodecenol, Octadienol, Decadienol Dodecadienol, oleyl alcohol, ricinoleyl alcohol, ercoalcohol Lauryl alcohol, stearyl alcohol, isostearyl alcohol, cetyl alcohol, lauryl alcohol Alcohol, myristyl alcohol, arachidyl alcohol, caprylic alcohol, caprylic alcohol Behenyl alcohol, linoleyl alcohol, linolenyl alcohol and behenyl alcohol These can be listed as 'L' and these 'Gerbet' alcohols. This list is available upon request. In some cases, the formula can be expanded to include other alcohols that are structurally or chemically related. Fatty alcohols are preferably derived from natural fatty acids, and usually from the corresponding esters of fatty acids. Prepared by reduction. Aliphatic compounds formed by reduction from naturally occurring fats and fatty oils. Coal fractions, for example, beef tallow, peanut oil, rapeseed oil, cottonseed oil, soybean oil, sunflower oil Palm kernel oil, linseed oil, corn oil, castor oil, rapeseed oil, sesame oil, cocoa butter Cocoa fat can also be used.

[0175] The following are also treatment substances that can be preferably combined with the composition according to the present invention. Possible examples: Ceramide, N-acylsphingosine (Sph Ingosine fatty acid amides) or synthetic analogs of such lipids (so-called pseudo-ceramides) These are such that they clearly improve the water-retaining capacity of the stratum corneum; phospholipids, for example, soybean residone Chin, egg lecithin and cephalin; Vaseline, paraffin and silicone oil The latter includes dialkyl- and alkylaryl-siloxanes, for example, dimethylpropyl Risiloxane and methylphenylpolysiloxane, as well as their alkoxylated forms This includes quaternized derivatives.

[0176] Hydrolyzed animal and / or plant proteins also contain the composition according to the present invention. It can be advantageously added to the preparation. Advantageous examples in this regard include, in particular, elastin, co Milk protein, keratin, milk protein, soy protein, oat protein, bean protein Protein, almond protein and wheat protein fraction or corresponding hydrolyzed protein Examples include nitrates, condensates with these fatty acids, and quaternary hydrolyzed proteins. The use of hydrolyzed plant protein is preferred.

[0177] Cosmetics or skin disease preparations containing the composition according to the present invention are solutions or lotions. If so, the following solvents can be used: water or aqueous solution; fats Oils, fats, waxes and other natural and synthetic fats, preferably fatty acids and low C content Esters with alcohols, for example, isopropanol, propylene glycol, This is an ester of glycerol, or an aliphatic alcohol, with an alkanic acid having a low carbon number. or esters with fatty acids; alcohols, diols or polyols with a low carbon number These ethers, preferably ethanol, isopropanol, and propylene glycol, are also used. glycerol, ethylene glycol, ethylene glycol monoethyl or monobutyl Ether, propylene glycol monomethyl, monoethyl or monobutyl ether, di Ethylene glycol monomethyl or monoethyl ether and similar products. The above dissolve Mixtures of the medium are particularly used. In the case of alcoholic solvents, water is an additional component. It is possible.

[0178] Cosmetics or pharmaceutical preparations containing the composition according to the present invention are also, according to the first aspect of the present invention. The composition may also contain antioxidants different from those used in cosmetics and / or Any antioxidant that is appropriate or conventional for use in skin diseases can be used. Antioxidants include amino acids (e.g., glycine, histidine, tyrosine, tryptophan). ) and their derivatives, imidazoles (e.g., urocanic acid) and their derivatives, Peptides, for example, D,L-carnosine, D-carnosine, L-carnosine and these Derivatives of carotenes (e.g., anserine), carotenoids, carotenes (e.g., α-carotene, β-carotene) (e.g., rhotenes, lycopene) and their derivatives, lipoic acid and its derivatives (e.g., dihydrochloride) (Po acid), gold thioglucose, propylthiouracil and other thiols (e.g., thiole Doxin, glutathione, cysteine, cystine, cystamine and their glycosyl forms N-acetyl, methyl, ethyl, propyl, amyl, butyl and lauryl, palmito (Iyl, oleyl, γ-linoleyl, cholesteryl and glyceryl esters) and this Salts of thiodipropionate, dilauryl thiodipropionate, distearyl thiodipropionate, thiodipropionate Pionic acids and their derivatives (esters, ethers, peptides, lipids, nucleotides, Nucleosides and salts) and sulfoximine compounds (e.g., butionine sulfoximine) Homocysteine ​​sulfoximine, butionine sulfone, penta-, hexa-, hepta -Thionine sulfoximine) (These are at very low tolerable doses), and also (metals) Chelating agents, such as α-hydroxy fatty acids, palmitic acid, phytic acid, lactoferrin α-hydroxy acids (e.g., citric acid, lactic acid, malic acid), humic acid, bile acids, bile extracts Substances, bilirubin, biliverdin, EDTA, EGTA and their derivatives, unsaturated fats Acids and their derivatives (e.g., gamma-linolenic acid, linoleic acid, oleic acid), folic acid and Biso derivatives, ubiquinone and ubiquinol and their derivatives, vitamin C and Its derivatives (for example, ascorbyl palmitate, magnesium ascorbyl phosphate, etc.) Scorbyl acetate), tocopherol and their derivatives (e.g., vitamin E acetate), Cetate), vitamin A and its derivatives (e.g., vitamin A palmitate), and further Benzoin resin coniferyl benzoate, rutinic acid and its derivatives, ferulic acid (f errulic acid) and its derivatives, butylhydroxytoluene, butylhydroxytoluene Roxyanisole, nordihydroguaiacinate, nordihydroguaiaretinate, tri Hydroxybutyrophenone, uric acid and its derivatives, mannose and its derivatives, zinc and its derivatives (e.g., ZnO, ZnSO4), selenium and its derivatives (e.g., selenium Lenmethionine), stilbene and their derivatives (e.g., stilbene oxide, t rans-stilbene oxide), and derivatives of the active compound (e.g., salts, es (Tel, ether, sugar, nucleotide, nucleoside, peptide, and lipid), for example, this Selected from the group consisting of those suitable according to the invention.

[0179] Cosmetics or pharmaceutical preparations containing the composition according to the present invention also contain vitamins and vitamins It may also contain a precursor and is suitable for cosmetic and / or skin disease applications. Any conventional vitamins and vitamin precursors can be used. and vitamin precursors, such as tocopherol, vitamin A, nicotinic acid and nicotine I would like to specifically mention amides, other B-complex vitamins, especially biotin, and vitamin C here. It is possible. Another example in this group that is preferred for use is pantothenyl alcohol. ions and their derivatives, particularly their esters and ethers, and cationically obtained particles Derivatives of pantothenyl alcohol, for example, pantothenyl alcohol triacetate, Pantothenyl alcohol monoethyl ether and its monoacetate and also cathyaluronic acid Examples include ionic pantothenyl alcohol derivatives.

[0180] Cosmetics or pharmaceutical preparations containing the composition according to the present invention also have a whitening effect. It may contain sex compounds and is suitable for cosmetic and / or skin disease applications. Any conventional whitening active compound can be used in accordance with the present invention. Among the beneficial whitening active compounds, kojic acid and hydro contain whitening stilbene derivatives. Quinone, arbutin, ascorbic acid, magnesium ascorbyl phosphate, resorcinol Licorice root extract and its components glabridin or licochalcone A, or extracts from Rumex and Ramulus species, or extracts from pine species (Pinus) Other examples include extracts from the Bithys species.

[0181] Cosmetic preparations containing the composition according to the present invention also have an active skin tanning effect. It may contain compounds and is suitable or appropriate for cosmetic and / or skin disease applications. Any commonly used skin tanning active compound can be used. Dihydroxyacetone (D HA (1,3-dihydroxy-2-propanone) can be given as an example here. DHA may be provided in either monomer or dimer form, and the proportion of dimers It is the dominant crystalline form.

[0182] Cosmetics or pharmaceutical preparations containing the composition according to the present invention also contain monosaccharides, disaccharides and o Ligosaccharides, such as glucose, galactose, fructose, mannose, and lactose. It can also contain -.

[0183] Cosmetics or pharmaceutical preparations containing the composition according to the present invention also contain plant extracts. It is also possible to do this, and these are usually prepared by extracting the complete plant, but individual cases are It can be prepared solely from the flowers and / or leaves of a plant, wood, bark, or roots. According to the present invention Regarding plant extracts that can be used, in particular, Leitfaden zur I nhaltsstoffdeklaration kosmetischer Mitt el(Guide to the Declaration of Constitution nts of Cosmetic Agents), Industrieverband Koerperpflegemittel und Waschmittel eV .(IKW)(Industrial Association for Toilet (Published by Ries and Detergents), Frankfurt, 3rd edition, page 44. Please refer to the extracts listed in the table starting with "ra". Particularly advantageous extracts include aloe and Ha mamelis, algae, oak bark, willow grass, nettle, lamium, hops, duck Meal, yarrow, arnica, calendula, burdock root, horsetail, hawthorn, linden Blossoms, cucumbers, almonds, pine needles, horse chestnut, sandalwood, juniper - Coconut, mango, apricot, orange, lemon, lime, grapefruit, apple Green tea, grapefruit seeds, wheat, oats, barley, sage, thyme, basil Rosemary, birch, mallow, buckthorn, willow bark, cinquefoil, Examples include coltsfoot, velvet ginger, ginseng, and ginger root. In particular, preferred extracts include aloe vera, chamomile, algae, rosemary, and calendula. Jura, ginseng, cucumber, sage, nettle, linden blossom, arnica and Hamamelis is one example. A mixture of two or more plant extracts can also be used. Yes, it is possible. Extracting agents that can be used to prepare the aforementioned plant extract include water, and Examples include alcohols and mixtures thereof. Preferred alcohols in this context are: Lower alcohols, such as ethanol and isopropanol, but polyhydric alcohols, For example, ethylene glycol, propylene glycol, and butylene glycol are also preferred. Specifically, both as a sole extractant and as a mixture with water are preferable. As indicated, plant extracts can be used in pure or diluted form.

[0184] Cosmetic or pharmaceutical preparations containing the composition according to the present invention are also particularly crystalline or fine When a crystalline solid, such as an inorganic micropigment, is incorporated into the preparation according to the present invention, anio It may contain cationic, nonionic, and / or amphoteric surfactants. Surfactants are amphiphilic substances that can dissolve organic and nonpolar substances in water. Surfactants are generally classified according to the properties and charge of the hydrophilic portion of their molecules. There are four groups. Here, they can be differentiated into: anionic surfactants, cationic surfactants, and amphoteric surfactants. Nonionic surfactants.

[0185] Anionic surfactants typically have carboxylate, sulfate, or sulfonate groups. It contains as a functional group. In aqueous solution, these are organic compounds that are charged with an electric load in an acidic or neutral medium. It forms an ON. Cationic surfactants are almost completely neutral due to the presence of a quaternary ammonium group. They are uniquely characterized. In aqueous solution, they are positively charged organic compounds in acidic or neutral media. It forms anions. Amphoteric surfactants contain both anionic and cationic groups, however Depending on the pH value, it behaves like an anionic or cationic surfactant in an aqueous solution. These substances have a positive charge in strongly acidic media and a negative charge in alkaline media. Neutral In contrast, in the pH range, these are amphoteric. The polyether chain is a nonionic interface. This is a typical example of an surfactant. Nonionic surfactants do not form ions in aqueous media.

[0186] Anionic surfactants that can be used advantageously include the following: acylu Mino acids (and their salts), for example, acyl glutamates, for example, acyl glutamic acid Sodium, di-TEA-palmitoyl aspartate and caprylic / capric acid Sodium glutamate; acyl peptides, e.g., palmitoyl hydrolyzed milk protein, co Cocoyl hydrolyzed soy protein sodium and cocoyl hydrolyzed collagen sodium Potassium sarcosinate, e.g., myristoyl sarcosine, lauroyl sarcosine TEA, sodium lauroyl sarcosinate and sodium cocoyl sarcosinate; tau Rates, for example, sodium lauroyl taurate and methyl cocoyl sodium taurate. Um; Acyl lactylate, e.g., lauroyl lactylate and caproyl lactylate; A Laninates; carboxylic acids and derivatives, e.g., lauric acid, aluminum stearate. , magnesium alkanolates and zinc undecylate; ester carboxylic acids, for example, Stearoyl lactylate calcium, laureth-6 citrate and PEG-4 lauryl Sodium midocarboxylate; ether carboxylic acids, e.g., sodium laureth-13 carboxylate Sodium phosphate and PEG-6 cocamide carboxylate; phosphate esters and salts, e.g. DEA-oleth-10 phosphate and dilaureth-4 phosphate; sulfonic acid and Salt, e.g., acyl isethionate, e.g., sodium cocoyl isethionate / ammonium Alkylaryl sulfonates; alkyl sulfonates, e.g., coco monoglycerides Sodium sulfonate, sodium olefin (C12-14) sulfonate, lauryl sulfonate Sodium phoacetate and PEG-3 cocamide magnesium sulfate; sulfosuccinate, e.g. For example, dioctyl sodium sulfosuccinate, disodium laureth sulfosuccinate, Disodium lauryl sulfosuccinate and undecylenamide sulfosuccinate MEA-2 Sodium; and sulfate esters, such as alkyl ether sulfates, such as laureth sulfate. Sodium laureth sulfate, ammonium laureth sulfate, magnesium laureth sulfate, M laureth sulfate IPA, TIPA laureth sulfate, sodium myreth sulfate, and C12-13 pareth sulfate Thorium, and alkyl sulfates, such as sodium lauryl sulfate and ammonium lauryl sulfate. TEA-145 and lauryl sulfate.

[0187] Examples of cationic surfactants that can be used advantageously include alkylamines and alkyl Examples include imidazoles, ethoxylated amines, and quaternary surfactants.

[0188] Quaternary surfactants are covalently bonded to at least one alkyl or aryl group. It contains several N atoms. This gives a positive charge regardless of the pH value. Alkyl betaine, Alkylamidopropyl betaine and alkylamidopropyl hydroxysulfane ( Hydroxysulphaine is advantageous. The cationic surfactant used is Furthermore, preferably, quaternary ammonium compounds, particularly benzyltrialkylammonium chloride. ammonium or benzyltrialkylammonium bromide, for example, benzyldimethyl chloride tharylammonium, as well as alkyltrialkylammonium salts, for example, cecochloride Cetyltrimethylammonium or cetyltrimethylammonium bromide, alkyl chloride Methylhydroxyethylammonium or alkyldimethylhydroxyethylammonium bromide Monium, dialkyldimethylammonium chloride, or dialkyldimethylammonium bromide Um, alkylamidoethyltrimethylammonium ether sulfate, alkylpi Lydinium salts, such as laurylpyridinium chloride or cetylpyridinium chloride, imida Zoline derivatives and cationic compounds, for example, amine oxides, for example, alkyl Choose from didimethylamine oxide or alkylaminoethyldimethylamine oxide. It is possible. Cetyltrimethylammonium salt can be used particularly advantageously. .

[0189] As an amphoteric surfactant that can be used advantageously, acyl / dialkylethylenediamine Min, for example, sodium acylamphoacetate, disodium acylamphodipropionate, Disodium alkylamphodiacetate, amphohydroxypropyl acyl sodium sulfonate Um, disodium acylamphodiacetate and sodium acylamphopropionate; N -Alkyl amino acids, e.g., aminopropylalkylglutamide, alkylaminopropyl Onic acid, sodium alkylimidodipropionate and lauroamphocarboxyglyceride Nate is one example.

[0190] Nonionic surfactants that can be used advantageously include alcohols and alkanols. Amides, e.g., cocamide MEA / DEA / MIPA; amine oxides, e.g., cocoa Midopropylamine oxide; carboxylic acid oxides of ethylene, glycerol, sorbitan or esters formed by esterification with other alcohols; ethers, for example, ethers Xylated / propoxylated alcohols, ethoxylated / propoxylated esters, ethoxylated / propoxylated alcohols Propoxylated glycerol ester, ethoxylated / propoxylated cholesterol, ethoxy Ethoxylated / propoxylated triglyceride esters, ethoxylated / propoxylated lanolin, ethoxy Polysiloxanes (siloxanes / propoxylated), propoxylated POE ethers, and alkyl polysulfates Lycosides, for example, lauryl glucoside, decyl glycoside, and coconut glycoside; Rose esters and ethers; polyglycerol esters, diglycerol esters, Examples include monoglycerol esters, methyl glucose esters, and hydroxy acid esters. It is possible.

[0191] Anionic and / or amphoteric surfactants and one or more nonionic surfactants The use of a combination of the following is also advantageous. The surfactant is a histamine release inhibitor according to the present invention. In a preparation containing the agent, at a concentration between 1 and 98% (m / m) relative to the dry weight of the preparation: It can exist.

[0192] Cosmetics or pharmaceutical preparations containing the composition according to the present invention are in a form suitable for topical use. For example, lotions, aqueous or aqueous-alcohol gels, vesicle dispersants, and These are simple or complex emulsions (O / W, W / O, O / W / O or W / O / W), liquid Body, semi-liquid or solid, for example, milk, cream, gel, cream-gel, It can also be formulated as a paste or stick, and optionally as an aerosol. It can be packaged as is, or it can take the form of a mousse or spray. These compositions are prepared by conventional methods.

[0193] To prepare the emulsion, the oil phase can be advantageously selected from the following group of substances: Oils, mineral waxes; fatty oils, fats, waxes, and other natural and synthetic fats, preferred These are fatty acids and alcohols with a low carbon number, such as isopropanol and propylene Esters with glycol or glycerol, or aliphatic alcohols with a low C number Esters with alkanic acids or fatty acids; alkyl benzoates; silicone oils, For example, dimethylpolysiloxane, diethylpolysiloxane, diphenylpolysiloxane and its mixed forms. Advantageously, saturated and / or having a chain length of 3 to 30 carbon atoms. Alternatively, unsaturated, branched and / or linear alkanecarboxylic acids and chains of 3 to 30 carbon atoms. Ester with saturated and / or unsaturated, branched and / or linear alcohols having length Aromatic carboxylic acids, with a chain length of 3 to 30 carbon atoms, saturated and / or unsaturated. You can use esters from the group of esters with sum, branched, and / or linear alcohols. It can be used. Preferred ester oils include isopropyl myristate and isopropyl palmitate. Isopropyl stearate, isopropyl oleate, n-butyl stearate, n-hexyl ureate, n-decyl oleate, isooctyl stearate, stearyl Isononyl benzoate, Isononyl isononanoate, 2-ethylhexyl palmitate, 2-ethylhexyl Hexyl laurate, 2-hexyldecyl stearate, 2-octyl palmitate Decyl, oleyl oleate, oleyl erucate, erucyl oleate, erucate erucate Examples include the synthesis, semi-synthesis, and natural mixtures of such esters, such as jojoba oil. It is possible.

[0194] The oil phase also includes branched and linear hydrocarbons and waxes, silicone oils, and dialkyl acids. The group containing tel, saturated or unsaturated, branched or linear alcohols, and fatty acid triglycerides The group including, specifically, saturated and having chain lengths of 8-24, particularly 12-18 C atoms. / or unsaturated, branched and / or linear alkanecarboxylic acid triglycerol esters It is also possible to make advantageous choices from among them. Fatty acid triglycerides are, for example, synthetic and semi-synthetic. and natural oils, such as olive oil, sunflower oil, soybean oil, peanut oil, rapeseed oil, and It is possible to advantageously select from a group that includes mond oil, palm oil, coconut oil, palm kernel oil, etc. Any mixture of such oil and wax components can also be used advantageously. In some cases, wax, such as cetyl palmitate, may be the sole lipid component of the oil phase. It is also advantageous to use 2-ethylhexyl isostearate, octyl Dodecanol, isotridecyl isononanoate, isoeicosane, 2-coconut oil fatty acid Tylhexyl, C12-15 alkyl benzoate, caprylic / capric triglyceride And are favorably selected from the group consisting of dicaprylyl ether. C12-15 Benzoate A mixture of lukyl and 2-ethylhexyl isostearate, C12-15 alkyl benzoate A mixture of isotridecyl isononanoate and C12-15 alkyl benzoates, 2 -A mixture of ethylhexyl isostearate and isotridecyl isononanoate is particularly It is advantageous for [the following]. Hydrocarbon paraffin oils, squalane, and squalene can also be used advantageously. The oil phase may also advantageously contain cyclic or linear silicone oil or It can also be complete from this, but in addition to one or more silicone oils, other oil phases The additional content of the active ingredient is preferably used. Cyclomethicone (e.g., decamethylcy) Clopentasiloxane can be advantageously used as a silicone oil. However, other Silicone oils, for example, undecamethylcyclotrisiloxane, polydimethylsiloxane methylphenylsiloxane can also be used advantageously. Cone and isotridecyl isononanoate, and cyclomethicone and 2-ethylhexyl A mixture of luisostearates is also particularly advantageous.

[0195] The aqueous phase of the preparation containing the composition according to the present invention, provided in the form of an emulsion, has a low C number Alcohols, diols, or polyols having these properties, and ethers thereof, preferably Ethanol, isopropanol, propylene glycol, glycerol, ethylene glyco ethylene glycol monoethyl or monobutyl ether, propylene glycol Monomethyl, monoethyl or monobutyl ether, diethylene glycol monomethyl or monoethyl ethers and similar products, as well as alcohols with a low number of carbon, e.g. For example, ethanol, isopropanol, 1,2-propanediol, glycerol and In particular, one or more thickening agents can be mentioned, and these thickening agents include silicon dioxide and aluminum silicate. The group includes nium, polysaccharides, and their derivatives, for example, hyaluronic acid, xanthan gum. , hydroxypropyl methylcellulose, particularly advantageously, the group including polyacrylates, preferred More specifically, polyacrylates derived from the group including so-called Carbopol, for example, Carbopol Models 980, 981, 1382, 2984, and 5984, respectively, either by themselves or in combination. By combining them, you can make a more advantageous choice.

[0196] A cosmetic or pharmaceutical preparation containing the composition according to the present invention, provided in the form of an emulsion, One or the other commonly used in the art for preparing cosmetic or pharmaceutical preparations It contains multiple emulsifiers in an advantageous proportion.

[0197] Cosmetics or pharmaceutical preparations containing the composition according to the present invention may also be used as cosmetics or A pharmaceutically acceptable carrier, for example, one of the following commonly used in the art: May contain (but is not limited to): lactose, glucose, sucrose, sol Bitol, mannitol, starch, acacia gum, calcium phosphate, alginate, Gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose Water, syrup, methylcellulose, methylhydroxybenzoate, propylhydro Xybenzoate, talc, magnesium stearate, mineral oil, etc. Cosmetic or pharmaceutical The preparation also contains, in addition to the above components, a lubricant, a humectant, a sweetener, a flavoring agent, an emulsifier, and a suspension. It may contain liquids, preservatives, etc. Appropriate pharmaceutically acceptable carriers and preparations are R emington's Pharmaceutical Sciences (19th edition, This is described in detail in 1995.

[0198] Pharmaceutical preparations may be administered orally or parenterally.

[0199] The appropriate dosage of the pharmaceutical preparation according to the present invention depends, for example, on the formulation method, age, weight, and sex. or conditions caused by the disease, food, administration time, route of administration, elimination rate, and patient response sensitivity. It can be prescribed in various ways depending on factors such as these.

[0200] The pharmaceutical composition according to the present invention is in unit dosage form and can be used by an average person skilled in the art to which the present invention relates. Using a pharmaceutically acceptable carrier and / or excipient in a method that can be easily implemented It may be manufactured by formulation.

[0201] Finally, the present invention relates to a stabilizer or avenanthramide for stabilizing avenanthramide. Regarding the use of mids, particularly compositions containing avenanthramide C, the stabilizer is a chelating agent, 2- Selected from the group consisting of organic acids having 10 carbon atoms, antioxidants, and mixtures thereof. It will be done.

[0202] The present invention is described with reference to specific and preferred variations, but the spirit of the invention is And without deviating from the scope, various changes can be made to the form and details. Those skilled in the art will understand that this is possible. Furthermore, the present invention applies to all possible variations. And unless otherwise specifically pointed out, any combination of the elements listed above is acceptable. To include.

[0203] In addition, although the features or aspects of the present invention are described in terms of the Markush group, Therefore, the present invention also applies to any individual member or subgroup of a member of the Markush group. I am aware of what is written here, based on that point of view.

[0204] The present invention is described in detail herein with reference to the following embodiments, but these embodiments are merely examples of the present invention. Since these are illustrative examples of the invention, the content of the present invention is not limited to the following embodiments, or is limited to the following embodiments. It won't happen. [Examples]

[0205] Example 1: Stabilization of Avn-containing DragoCalm® extract using different stabilizers Qualitative testing

[0206] The following DragoCalm® extracts, which contain different stabilizers The oxidative stability of a glycerol / water-based solution is compared to that of an oat extract without stabilizers. The evaluation was performed on a cerol / water-based solution.

[0207] Stability testing of DragCalm® was conducted using Mikrolab's Oxipres technology. Pre-form using a vise, or use a Xenotest440 apparatus (60W, 1294 kJ / m 2 Irradiation was performed for 6 hours using a wavelength of 300-400 nm.

[0208] The Oxipres device enables the determination of the oxidative resistance (storage life) of oil. This is a modified method of the cylinder method according to ASTM D941, and is based on oxidation by oxygen. The test is operated under high pressure and high temperature, which accelerates the decomposition process. During the test, acid The consumption of oxygen results in a pressure drop inside the container. A decrease in pressure leads to increased oxygen consumption. This suggests a higher oxidation rate in the test product. Oils with a high degree of unsaturation are most susceptible to auto-oxidation. It is also susceptible to oxidation. Sunflower oil is an oil with a high concentration of unsaturated fatty acids, and therefore it is susceptible to oxidation. To bring about.

[0209] The device also simulates storage conditions for substances that do not contain unsaturated fatty acids. This makes it possible.

[0210] The following test conditions are equivalent to the storage of DragoCalm® at 40°C for one month. This corresponds to, for example, more difficult conditions in temperature and pressure, which adds This is a rapid stability test. DragoCalm® is a blend of the following: [Table 2]

[0211] Test procedure: Stir at room temperature or, if necessary, at a temperature of 40-50°C, adding the stabilizer to DragoC Pre-dissolved in alm(registered trademark) (i.e., hydroxyacetophenone). Dra Place the goCalm® sample (15g) in the reaction vessel and use the Oxipres device. Using a device, the subjects were exposed to 5 bar of oxygen at 70°C for 24 hours.

[0212] The sample was evaluated, i.e., the Avns content was determined by HPLC (Oxipre (Comparison of before and after processing by s).

[0213] The content of avenanthramide C was determined by HPLC before and after Oxipres treatment. Ta.

[0214] Glycine of the previously described DragoCalm® extract using different stabilizers The color stability of cerol / water-based solutions is improved by glycerol from oat extract without stabilizers. The evaluation was performed on a water-based solution.

[0215] Furthermore, the color of the DragoCalm® sample is controlled by the L*a*b* system (Lic Measurements were taken before and after treatment with Oxipres using o690). b* The values ​​describe discoloration in the yellowish / reddish / brownish regions, and the Δb* value is O This section describes the difference in color before and after processing with Xipres. A higher Δb* value indicates a greater difference in color. The test solution has changed color more.

[0216] Table 2 below shows the results of determining avenanthramide C and color measurement after Oxipres treatment. Includes.

[0217] [Table 3-1] [Table 3-2] [Table 3-3]

[0218] The addition of a combination of acids, chelating agents, and antioxidants improves the stability of avenanthramide C. It was clearly observed that it brought about positive results. Furthermore, the tested samples showed little discoloration. I was also able to show things that I hadn't shown before.

[0219] Furthermore, we observed improved stability of avenanthramide L with the addition of a stabilizer. And it was done.

[0220] The test procedure and evaluation of the samples are carried out in the same manner as described above, using the avenance lumens. It was done against D C.

[0221] [Table 4-1] [Table 4-2]

[0222] The addition of stabilizers improves the stability of avenanthramide L. The stability can be further synergistically improved by adding the following combination of stabilizers, as shown above. The results clearly show: 4-Hydroxyacetophenone + Ascorbic Acid Symdecanox DPG + Citric Acid Symdecanox DPG + Ascorbic Acid

[0223] Furthermore, improved stability of avenanthramide B was observed with the addition of a stabilizer. Done.

[0224] The test procedure and evaluation of the sample are the same as those described above for avenanthramide C. It was done using the same method.

[0225] [Table 5-1] [Table 5-2]

[0226] The addition of stabilizers improves the stability of avenanthramide B. The above results indicate that stability can even be improved synergistically by adding the following combination of stabilizers. This clearly shows: Ascorbic acid + tetrasodium glutamate diacetate; Citric acid + tetrasodium glutamate diacetate; 4-hydroxyacetophenone + ascorbic acid; Phytic acid + tetrasodium glutamate diacetate; Phytic acid + ascorbic acid; Phytic acid + 4-hydroxyacetophenone; Tetrasodium glutamate diacetate + 4-hydroxyacetophenone; Disodium EDTA + ascorbic acid + citric acid.

[0227] Example 2: Stability test of dihydroavennanceramide D (before and after UV stress treatment)

[0228] Dihydroavennanthramide D is more stable than avenanthramide C, but U It is well known that post-treatment decomposition occurs due to V stress.

[0229] To evaluate the effect of different stabilizers on the stability of dihydroavennanceramide D, Prepare the following solutions (Solutions A-D, Solution A serves as a comparison) and perform a UV stress test on 6 Time processing was performed.

[0230] The content of dihydroavennanceramide D was measured by HPLC before and after UV stress treatment. The Δb* value was determined and then calculated. The Δb* value corresponds to the grade of the yellow / brownish solution. This provides additional information. A higher Δb* value suggests more discoloration.

[0231] [Table 6]

[0232] By heating the solution to 50°C, dihydroavennanceramide D is converted to dipropylene. The solution was dissolved beforehand during the recall. Water was added and stirred until a homogeneous solution was achieved.

[0233] Test conditions: UV stress test: Xenotest440 Device 6 hours 1294 kJ / m³ 2 Wavelength 300~400nm

[0234] [Table 7] We observed that the following combinations resulted in improved stability of dihydroavennanceramide D. I was able to: Ascorbic acid + Citric acid SymDecanox DPG + Citric Acid SymDecanox DPG + Tetrasodium Glutamate Diacetate

[0235] Oat extract stabilized with at least one stabilizer is comparable to oat extract without stabilizers. The results in Tables 2-4 and 6 clearly show that the extract is more stable against degradation and discoloration. This indicates that certain combinations of stabilizers cause degradation of avenanthramide and embers. Extracts and avenanthramide analog compounds, particularly dihydroavenanceramide D, are color-safe. The results clearly demonstrate that it even has a synergistic effect on qualitative analysis.

[0236] Example 3: Formulation Example

[0237] [Table 8-1] [Table 8-2]

[0238] [Table 9]

[0239] [Table 10]

[0240] [Table 11]

[0241] [Table 12]

[0242] The above fragrance oils PO1, PO2, PO3, PO4, or PO5 are prepared separately in each case. The following preparations / formulations were obtained.

[0243] Cosmetic preparations / formulations (quantity is weight %) relative to all preparations / formulations

[0244] Table 13

[0245] Table 14

[0246] Table 15-1 Table 15-2

[0247] Table 16-1 Table 16-2

[0248] Table 17

[0249] Table 18

[0250] Table 19

[0251] Table 20-1 Table 20-2

[0252] Table 21-1 Table 21-2

[0253] Table 22-1 Table 22-2

[0254] Table 23-1 Table 23-2

[0255] Table 24-1 Table 24-2

[0256] Table 25-1 Table 25-2

[0257] Table 26

[0258] Table 27

[0259] Table 28

[0260] Table 29

[0261] Table 30

[0262] Table 31

[0263] Table 32 Table 33

[0264] Table 34

[0265] Table 35

[0266] Table 36

[0267] Table 37

[0268] Table 38

[0269] Table 39

[0270] Table 40

[0271] Table 41

[0272] Table 42-1 Table 42-2

[0273] Table 43

[0274] Table 44

[0275] Table 45

[0276] Table 46

[0277] Table 47

[0278] Table 48

[0279] Table 49

[0280] Table 50

[0281] Table 51

[0282] Table 52

[0283] Table 53-1 Table 53-2 Table 53-3 Table 53-4 Table 53-5 Table 53-6 Table 53-7

[0284] Table 54

[0285] Table 55

Claims

1. - A composition comprising or consisting of at least one avenanthramide and at least one stabilizer, (a1) At least one avenanthramide is avenanthramide C, (a2) At least one stabilizer is selected from the group consisting of EDTA or its salts, ascorbic acid, citric acid, lactic acid, 4-hydroxyacetophenone, malic acid, tartaric acid, tetrasodium glutamate diacetate, trisodium ethylenediaminedisuccinate, phytic acid, 6-parador, and mixtures thereof, or (b1) At least one avenanthramide is avenanthramide L, (b) At least one stabilizer is selected from the group consisting of EDTA or its salts, trisodium ethylenediaminedisuccinate, malic acid, tartaric acid, and mixtures thereof, or (c1) At least one avenanthramide is avenanthramide B, (c2) A composition in which at least one stabilizer is selected from the group consisting of EDTA or a salt thereof, ascorbic acid, trisodium ethylenediaminedisuccinate, malic acid, and mixtures thereof.

2. At least one avenanthramide selected from the group consisting of avenanthramides A, B, C, G, H, K, L, and R and mixtures thereof, At least two stabilizers selected from the group consisting of chelating agents, organic carboxylic acids having 2 to 10 carbon atoms, antioxidants, and mixtures thereof, A composition containing or comprising the following: The chelating agent is selected from the group consisting of EDTA or its salts, phytic acid, tetrasodium glutamate diacetate, trisodium ethylenediamine disuccinate, and trisodium methylglycine diacetate. The organic carboxylic acid is selected from alpha hydroxy acids selected from the group consisting of lactic acid, malic acid, citric acid, and tartaric acid. A composition in which the antioxidant is selected from the group consisting of 4-hydroxyacetophenone, ascorbic acid, 6-parador, ascorbyl palmitate, ascorbyl phosphate and their salts, sodium ascorbate and allantoin.

3. Dihydroavennthramide D, an avenanthramide analog, At least two stabilizers selected from the group consisting of tetrasodium glutamate diacetate, citric acid, ascorbic acid, 6-paradol, ascorbyl palmitate, ascorbyl phosphate and their salts and sodium ascorbate, A composition containing or consisting of the following.

4. The composition according to claim 2, wherein at least two stabilizers are a combination of a chelating agent and an organic carboxylic acid, a combination of a chelating agent and an antioxidant, or a combination of an organic carboxylic acid and an antioxidant, or a combination of a chelating agent, an organic carboxylic acid and an antioxidant.

5. At least two stabilizers are required, in the following combinations of stabilizers: EDTA disodium and ascorbic acid; EDTA disodium and citric acid; EDTA disodium and 4-hydroxyacetophenone; EDTA disodium and lactic acid; EDTA disodium and malic acid; EDTA disodium and tartaric acid; EDTA disodium and phytic acid; Ascorbic acid and 4-hydroxyacetophenone; Ascorbic acid and tetrasodium glutamate diacetate; Phytic acid and tetrasodium glutamate diacetate; Phytic acid and ascorbic acid; Phytic acid and malic acid; 4-Hydroxyacetophenone and ascorbic acid; 4-Hydroxyacetophenone and phytic acid; 4-Hydroxyacetophenone and tetrasodium glutamate diacetate; 4-Hydroxyacetophenone and trisodium ethylenediaminedisuccinate; 6-Parador and EDTA disodium; 6-Paradol and citric acid; 6-Paradol and ascorbic acid; 6-Paradol and tetrasodium glutamate diacetate; EDTA disodium, ascorbic acid, and citric acid; The composition according to claim 2 or 4.

6. Based on the total weight of the composition, - 0.0001 to 5.0% by weight of at least one avenanthramide or its analogue, dihydroavenanceramide D; and - 0.02 to 0.5% by weight of at least one or two stabilizers A composition according to any one of claims 1 to 5, comprising:

7. Use as a non-therapeutic cosmetic of any one of claims 1 to 6 for skin protection and skin care, scalp protection and scalp care, hair care, nail care, or for moisturizing the skin, or for the prevention and / or treatment of skin aging, wrinkle formation, loss of skin volume, loss of skin elasticity, or pigmentation.

8. A composition according to any one of claims 1 to 6 for use as a pharmaceutical.

9. The composition according to claim 8, for the prevention and / or treatment of skin diseases or keratosis, barrier-related skin diseases or keratosis having inflammatory, immunoallergic, atherogenic, dry or hyperproliferative components, or for the prevention and / or treatment of skin diseases associated with increased ROS production, or for the prevention and / or treatment of serum LDL cholesterol and lipid levels, for reducing blood pressure, for improving insulin sensitivity, and for enabling control of blood glucose levels, in order to prevent and / or treat unbearable and sensitive skin, skin irritation, skin redness, skin conditions, dry skin, wheals, pruritus, and pigment abnormalities, or for the prevention and / or treatment of skin diseases or keratosis having inflammatory, immunoallergic, atherogenic, dry or hyperproliferative components, or for the prevention and / or treatment of skin diseases associated with increased ROS production, or for the prevention and / or treatment of cardiovascular diseases, allergic reactions, and coronary heart disease.

10. The composition according to claim 9, wherein the skin disease or keratinous disease is selected from the group consisting of eczema, psoriasis, seborrhea, dermatitis, erythema, pruritus (itching), inflammation, irritation, fibrosis, lichen planus, pityriasis rosea, tinea versicolor, autoimmune vesicular diseases, urticaria-like conditions, angiodermal and allergic skin reactions, and wound healing, and / or the skin disease associated with increased ROS production is selected from the group consisting of atopic dermatitis, neurodermatitis, psoriasis, rosacea, acneiform rash, xerosis, and xerosis.

11. Use of the composition according to any one of claims 1 to 6 for preparing food, nutritional supplements, cosmetics, pharmaceutical or veterinary preparations, dermatological or keratin preparations.

12. Food, nutritional supplement, cosmetic, pharmaceutical or veterinary preparation, or dermatological or keratin preparation, comprising the composition described in any one of claims 1 to 6 in an amount of 0.0001 to 10% by weight of the total weight of the preparation.

13. The food, nutritional supplement, cosmetic, pharmaceutical or veterinary preparation or dermatological or keratin preparation according to claim 12, further comprising: one or more active substances selected from the group consisting of skin moisturizing and / or water-retaining substances, cooling agents, osmolites, keratinous substances, nutrients, anti-inflammatory, antibacterial or antifungal substances, substances having redness-reducing or itchiness-reducing effects, analgesic substances, and any mixture thereof; and / or antioxidants, preservatives, (metal) chelating agents, penetration enhancers, surfactants, emulsifiers, fragrances, defoaming agents, colorants, pigments having coloring effects, thickeners, plasticizers, fats, oils, waxes, or other conventional components of cosmetic compositions, such as alcohols, polyols, polymers, foam stabilizers, electrolytes, organic solvents or silicone derivatives, and any mixture thereof, which are cosmetically or pharmaceutically acceptable excipients.

14. A food, nutritional supplement, cosmetic, pharmaceutical or veterinary preparation, or dermatological or keratin preparation according to claim 12 or 13, provided as a liquid, tincture, lotion, emulsion, gel, cream, ointment, spray or shampoo.

15. The use of the stabilizer according to claim 1, The stabilizer (a2) described in claim 1 is used to stabilize avenanthramide C or a composition containing avenanthramide C, in order to prevent their decomposition or discoloration, or The stabilizer (b2) described in claim 1 is used to stabilize avenanthramide L or a composition containing avenanthramide L in order to prevent their decomposition or discoloration, or Use of the stabilizer (c2) according to claim 1, for stabilizing avenanthramide B or a composition containing avenanthramide B, to prevent decomposition or discoloration thereof.

16. The use of at least two stabilizers to stabilize at least one avenanthramide, or a composition containing at least one avenanthramide, in order to prevent their degradation or discoloration, At least one avenanthramide is selected from the group consisting of avenanthramides A, B, C, G, H, K, L, and R and mixtures thereof. The stabilizer is selected from the group consisting of chelating agents, organic carboxylic acids having 2 to 10 carbon atoms, antioxidants, and mixtures thereof. The chelating agent is selected from the group consisting of EDTA or its salts, phytic acid, tetrasodium glutamate diacetate, trisodium ethylenediamine disuccinate, and trisodium methylglycine diacetate. The organic carboxylic acid is selected from alpha hydroxy acids selected from the group consisting of lactic acid, malic acid, citric acid, and tartaric acid. The antioxidant used is selected from the group consisting of 4-hydroxyacetophenone, ascorbic acid, 6-parador, ascorbyl palmitate, ascorbyl phosphate and its salts, sodium ascorbate, and allantoin.

17. The use of at least two stabilizers to stabilize dihydroavennthramide D, an avenanthramide analog, or a composition containing dihydroavennthramide D, an avenanthramide analog, in order to prevent their decomposition or discoloration, The stabilizer is selected from the group consisting of tetrasodium glutamate diacetate, citric acid, ascorbic acid, 6-paradol, ascorbyl palmitate, ascorbyl phosphate and its salts, and sodium ascorbate.

Images